**COVID-19 durante el embarazo: Revisión rápida y meta-análisis**

**Material suplementario**

**Suplemento-1. Estrategia de búsqueda en *PubMed*.**

|  |
| --- |
| ((“pregnancy” OR “pregnancy/complications” OR “gestational diabetes” OR “hypertension in pregnancy” OR “pregnancy related hypertension” OR “gestational hypertension” OR “pregnancy hypertension” OR “pre eclampsia” OR “eclampsia” OR “spontaneous abortion” OR “abortion” OR “threatened abortion” OR “miscarriage” OR “placenta previa” OR “premature labor” OR “maternal obesity” OR “obesity in pregnancy” OR “maternal death” OR “maternal mortality” OR “maternal complications” OR “labor induction” OR “pregnancy interruption” OR “termination of pregnancy” OR “pregnancy termination” OR “vaginal delivery” OR “cesarean section” OR “newborn infant” OR “childbirth” OR “perinatal” OR “perinatal outcomes” OR “perinatal complications” OR “apgar score” OR “neonatal complications” OR “neonatal intensive care” OR “neonatal icu” OR “neonatal intensive care unit” OR “neonatal asphyxia” OR “asphyxia neonatorum” OR “newborn complications” OR “birth weight” OR “premature birth” OR “small for gestational age” OR “newborn morbidity” OR “fetal death” OR “stillbirth”) AND (“2019 ncov” OR “2019ncov” OR “new coronavirus” OR “covid 19” OR “covid19” OR “novel coronavirus” OR “2019 novel coronavirus” OR “sarscov 2” OR “wuhan coronavirus” OR “sarscov”)) |

**Suplemento-2. Esquema de selección de artículos para la revisión.**

Documentos elegibles\*

312

Revisión de texto completo

93

Exclusiones

40 (revisiones/meta-análisis)

**Para extracción de datos:**

**86**

*(68con datos maternos y neonatales)*

*(11únicamente con datos maternos)*

*(7únicamente con datos neonatales)*

Eliminados

7

Descartados

179

\* Indizados en *PubMed* al 22/mayo/2020 en idioma inglés. Se incluyeron documentos no editados (*ahead of print, pre-proof, versiones aceptadas)* y cartas al Editor que reportaron casos maternos y/o neonatales relacionados las preguntas.

***Extracción de datos***

De cada estudio seleccionado se extrajeron datos de identificación (autores, año, diseño, país y hospital); tamaño de muestra (número de casos); edades (maternas y neonatales); semanas de gestación (SDG) al diagnóstico de COVID-19 y al parto (maternos). Los eventos maternos y neonatales se registraron por separado en hojas de Excel. Los eventos en las mujeres embarazadas fueron: 1) complicaciones asociadas al COVID-19 (ventilación mecánica, admisión a la Unidad de Cuidados Intensivos (UCI), coagulopatía, alteraciones renales, falla orgánica múltiple y muerte); 2) complicaciones propias del embarazo (diabetes gestacional [DG], preeclampsia, trastornos hipertensivos del embarazo excluyendo preeclampsia, placenta previa, ruptura prematura de membranas (RPM), sufrimiento fetal, desprendimiento de placenta, oligo y poli-hidramnios, trabajo de parto prematuro espontáneo y complicaciones en el post-parto); 3) enfermedades pre-existentes (diabetes tipo 2, hipertensión arterial crónica, obesidad, hipotiroidismo, asma, cardíacas y renales); y 4) vía de resolución del embarazo (indicaciones de cesáreas: COVID-19, obstétrica o electiva; parto vaginal; aborto espontáneo). Los eventos neonatales identificados fueron: 1) transmisión vertical; 2) neonatos positivos a SARS-CoV-2 con y sin neumonía; 3) complicaciones neonatales (puntaje Apgar al minuto y a los cinco minutos, pre-términos [extremos, <28SDG; moderados, 28-31SDG; y tardíos, 32-36SDG], bajo peso al nacer, sufrimiento fetal, aborto espontáneo, muerte fetal y muerte neonatal) e ingreso a la Unidad de Cuidados Intensivos Neonatales (UCIN). El puntaje Apgar se registró en rango, a partir del cual se generaron indicadoras (Apgar <7 o ≥7) para estimar el porcentaje de neonatos con puntaje óptimo. Adicionalmente, de cada estudio con grupo control se extrajo información sobre el tamaño de muestra, tipo de controles, edad, hospital, período de estudio; así como los datos de eventos maternos o neonatales de interés para calcular RM crudas como medidas de riesgo.

**Suplemento-3. Listados de los 86 estudios incluidos en la revisión.**

|  |  | **Mujeres embarazadas (N=1,042)** | | | | | | |  | **Neonatos (N=644)** | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Autor y Mes (2020)** | **País, Hospital** | **N** | **Edad (media)** | **Dx positivo(SDG)** | | **Parto (SDG)** | **Dx lab (n)** | **Dx clínico (n)** |  | **N** | **Apgar al min-5** | **Edad (días)** | **Transmisión vertical** |
| Ahmed I et al. Mayo1 | Reino Unido, Heartlands | 1 | 29 | 29 | | 31 | 1 | 1 |  | 1 |  |  |  |
| Alzamora MC et al. Abril2 | Perú | 1 | 41 | 33 | | 34 | 1 | 0 |  | 1 | 8 | 1 | 1 |
| Anderson J et al. Julio3 | EUA | 1 | 35 | 22 | | 0 | 1 | 1 |  | Sin datos neonatales | | | |
| Baergen RN et al. Mayo4 | EUA, Weill Cornell | 20 | 31 | 38 | |  | 20 |  |  | 21 | 8-9 |  |  |
| Baud D et al. Abril5 | EUA, Lausanne University | 1 | 28 | 19 | | 19 | 1 | 0 |  | 1 |  |  | 0 |
| Blauvelt CA et al. Mayo6 | EUA | 1 | 34 | 28 | | 29 | 1 | 1 |  | 1 | 8 |  | 0 |
| Blitz MJ et al. Abril7 | EUA, Multicéntrico | 82 | 31 |  | |  |  |  |  | Sin datos neonatales | | | |
| Breslin N et al. Abril8 | EUA, NY (Hospitales) | 43 | 30 | 37 | | 35 | 43 | 0 |  | 18 | ≥9 |  | 0 |
| Browne PC et al. Abril9 | EUA | 1 | 33 | 23 | | 0 | 1 | 0 |  | Sin datos neonatales | | | |
| Buonsenso D et al. Abril10 | Italia | 4 | 38 | 29 | | 38 | 4 | 4 |  | 2 |  |  |  |
| Buonsenso D et al. Mayo11 | Italia | Sin datos maternos | | | | | |  |  | 2 | 9-10 | 15 | 0 |
| Cao D et al. Abril12 | China, Hubei, Tongji | 10 | 30 | 37 | 38 | | 10 | 0 |  | 11 | 9-10 |  | 0 |
| Chen H et al, Febrero13 | China, Zhongnan | Sin datos maternos | | | | | |  |  | 6 | 9-10 | 2 | 0 |
| Chen R et al. Marzo14 | China, Renmin | 17 | 29 |  | 37 | | 17 | 0 |  | 17 | 9-10 |  | 0 |
| Chen R et al. Marzo15 | China, Renmin University | 1 | 27 | 36 | 36 | | 1 | 1 |  | 1 |  |  |  |
| Chen S et al. Marzo16 | China, Hubei | 5 | 29 | 39 | 39 | | 5 | 0 |  | 5 | 10 |  |  |
| Collin J et al. Mayo17 | Suecia | 13 | 28 | 27 | 0 | | 13 | 0 |  | Sin datos neonatales | | | |
| Cooke WR et al. Mayo18 | Reino Unido, Royal Berkshire | 2 | 34 | 29 | 29 | | 2 | 2 |  | 2 | 3 y 8 |  |  |
| Coronado Munoz A et al. Mayo19 | EUA | Sin datos maternos | | | | | |  |  | 1 |  | 21 |  |
| De Socio GV et al. Mayo20 | Italia, Santa María de lla Misericordia, Perugia | 1 | 33 | 40 | 40 | | 1 | 0 |  | 1 | 10 |  |  |
| Dória M et al. Mayo21 | Portugal, Pedro Hispano | 12 | 32 | 38 | 39 | | 12 | 0 |  | 11 | 9-10 |  |  |
| Du Y et al. Mayo22 | China, Xi’an Jiaotong University | 1 | 30 | 36 | 37 | | 1 | 1 |  | 1 | 9 |  |  |
| Fan C et al. Marzo23 | China, Renmin | 2 | 32 | 37 | 37 | | 2 | 0 |  | 2 | 10 |  | 0 |
| Ferrazzi E et al. Abril24 | Italia, Multicéntrico | 42 | 33 |  | 36 | | 42 |  |  | 42 | ≥7(40/42) | 2 |  |
| Gidlöf S et al. Abril25 | Suecia | 1 | 34 | 36 | 36 | | 1 | 0 |  | 2 | 10 |  | 0 |
| Govind A et al. Mayo26 | Reino Unido, North Middlesex | 9 | 31 | 39 |  | | 9 | 4 |  | 9 | 6-9 | 6 |  |
| Hantoushzadeh S et al. Abril27 | Irán, Multicéntrico | 9 | 37 | 31 |  | | 9 | 7 |  | 11 | 7-9( 5/9) | 7 |  |
| Hirshberg A et al. Mayo28 | EUA, Multicéntrico | 5 | 33 | 28 | 31 | | 5 | 5 |  | 3 | 4-9 |  |  |
| Hong L et al. Mayo29 | EUA, Henry Ford | 1 | 36 | 23 | 0 | | 1 | 0 |  | Sin datos neonatales | | | |
| Inchingolo R et al. Abril30 | Italia, Fondazione Policlínico Universitario Agostino Gemell | 1 |  | 23 | 0 | | 0 | 0 |  | Sin datos neonatales | | | |
| Iqbal SN et al. Abril31 | EUA, Washington | 1 | 34 | 39 | 39 | | 1 | 1 |  | 1 | 9 |  |  |
| Juusela A et al. Abril32 | EUA, Newark Beth Israel | 2 | 36 | 36 | 36 | | 2 | 2 |  | Sin datos neonatales | | | |
| Kalafat E et al. Abril33 | Turquía | 1 | 32 | 35 | 36 | | 1 | 0 |  | 1 | 9 |  | 0 |
| Kamali AM et al. Junio34 | Irán, Mousavi | Sin datos maternos | | | | | | |  | 1 |  | 15 |  |
| Karami P et al. Abril35 | Irán, Vali-e-asr | 1 | 27 | 30 | 30 | | 1 | 0 |  | 1 |  |  |  |
| Kelly JC et al. Abril36 | EUA | 1 |  | 33 | 33 | | 1 | 1 |  | 1 | 6 |  |  |
| Khan S, Jun L et al. Abril37 | China, Renmin | 17 | 29 | 38 | 38 | | 17 | 0 |  | 17 | 9-10 |  | 0 |
| Khan S, Peng L et al. Marzo38 | China, Renmin | 3 | 29 | 34 | 37 | | 3 | 0 |  | 3 | 9-10 |  | 0 |
| Khodamoradi Z. et al. Mayo39 | Irán | 1 | 36 | 0 | 0 | | 1 | 1 |  | Sin datos neonatales | | | |
| Kuhrt K et al. Mayo40 | Reino Unido, Saint Thomas | 1 | 30 | 32 | 33 | | 1 | 1 |  | 2 | 8 y 9 |  | 0 |
| Lang GJ et al. Mayo41 | China, First Affiliated, Zhejiang | 1 | 30 | 35 | 36 | | 1 | 1 |  | 1 | 10 |  | 0 |
| Lee DH et al. Marzo42 | Corea | 1 | 28 | 36 | 38 | | 1 | 0 |  | 1 | 10 |  | 0 |
| Li J et al. Mayo43 | China, Zhongshan | 1 | 31 | 35 | 35 | | 1 | 1 |  | 1 | 1 |  |  |
| Li N et al. Marzoa,44 | China, Hubei | 34 | 30 | 37 | 38 | | 16 | 18 |  | 36 | 10 |  | 0 |
| Li Y et al. Junio45 | China, Zhejiang | 1 | 30 | 35 | 35 | | 1 | 0 |  | 1 |  |  | 0 |
| Liao J et al. Abrilb,46 | China, Zhongnan | 10 | 32 | 39 |  | | 10 | 0 |  | 10 |  |  | 0 |
| Liu D et al Marzo47 | China, Tongji | 15 | 32 | 32 | 35 | | 15 | 0 |  | 11 | 8-9 |  | 0 |
| Liu W et al. Abril48 | China, Tongji | 19 | 31 | 39 | 39 | | 10 | 9 |  | 19 | 8-9 |  | 0 |
| Liu Y et al. Marzo49 | China, fuera de Wuhan | Sin datos maternos | | | | | | |  | 10 |  |  | 0 |
| Lokken EM et al. Mayo50 | EUA, Multicéntrico | 46 | 29 | 33 | 38 | | 46 | 46 |  | 8 |  |  |  |
| London V et al. Mayob,51 | EUA, Maimonides | 68 | 30 |  |  | | 68 |  |  | 48 |  | 0 |  |
| Lorenz N et al. Mayo52 | Alemania | Sin datos maternos | | | | | | |  | 1 | 9 |  | 0 |
| Lowe B et al. Abril53 | Australia | 1 | 31 | 40 | 40 | | 1 | 0 |  | 1 | 9 |  | 0 |
| Lu D et al. Abril54 | China, Anhui | 1 | 22 | 38 | 0 | | 1 | 0 |  | 1 | 9-10 |  | 0 |
| Lyra J et al. Abril55 | Portugal, Universitário de São João | 1 | 35 | 40 | 40 | | 1 | 0 |  | 1 | 9 |  |  |
| Martinelli I et al. Abril56 | Italia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlínico | 1 | 17 | 29 | 30 | | 1 | 1 |  | 1 | 0 |  |  |
| Mehta H et al. Mayo57 | EUA, Saint Barnabas | 1 | 39 | 27 | 28 | | 1 | 1 |  | 2 | 3-6 | 3 | 1 |
| Penfield CA et al. Mayo58 | EUA, NYU Langone Health | 11 | 32 | 37 | 38 | | 1 |  |  | 11 |  | 0 | 3 |
| Peng Z et al. Mayo59 | China | 1 | 25 | 34 | 35 | | 1 | 1 |  | 1 | 10 | 0 | 0 |
| Pereira A et al. Mayo60 | España, Puerta de Hierro Majadahonda | 60 | 34 | 32 |  | | 60 | 18 |  | 23 |  |  | 0 |
| Perrone S et al. Mayo61 | Italia, Parme | 4 | 33 | 34 | 39 | | 3 | 1 |  | 4 | 9-10 |  | 0 |
| Pierce-Williams RAM et al. Mayo62 | EUA, Multicéntrico | 64 | 33 | 31 |  | | 64 | 2 |  | 33 | 8 | 2 |  |
| Qadri F et al. Mayo63 | EUA, Beaumont | 16 | 30 | 31 |  | | 16 |  |  | 12 | 9 | 0 |  |
| Qiancheng X et al. Abrilb,64 | China, Wuhan | 28 | 30 | 38 |  | | 26 |  |  | 23 | 10 |  |  |
| Salvatori G et al. Abril65 | Italia | 2 | 31 | 40 | 0 | | 2 | 0 |  | 2 |  | 14 | 0 |
| Savasi VM et al. Febrero66 | Italia, Multicéntrico | 77 | 31 | 37 | 39 | | 77 | 13 |  | 57 | 4-10 | 3 |  |
| Schnettler WT et al. Abril67 | EUA, Health-Good Samaritan | 1 | 39 | 32 | 32 | | 1 | 1 |  | 1 |  | 0 |  |
| Shanes ED et al. Mayob,68 | EUA | 16 | 34 | 32 | 37 | | 16 | 0 |  | 16 | 9 |  |  |
| Sun M et al. Abril69 | China, Henan | 3 | 29 | 34 | 35 | | 3 | 3 |  | 3 | 5-9 | 6 | 0 |
| Taghizadieh A et al. Mayo70 | Iran, Imam Reza,Tabriz | 1 | 33 | 34 | 34 | | 1 | 1 |  | 1 |  |  |  |
| Vallejo V et al. Mayo71 | EUA | 1 | 36 | 37 | 37 | | 1 | 1 |  | 1 | 9 |  | 0 |
| Vlachodimitropoulou KE et al. Abril72 | Canadá/Francia | 2 | 32 | 35 | 36 | | 2 | 0 |  | 2 | 2 y 9 |  |  |
| Wen R et al. Marzo73 | China, Qingdao | 1 | 31 | 30 | 0 | | 1 | 0 |  | Sin datos neonatales | | | |
| Wu C et al. Abril74 | China, Qingdao | 8 | 26 | 38 |  | | 6 | 2 |  | Sin datos neonatales | | | |
| Wu X et al. Abril75 | China, Wuhan, Tongji | 23 | 29 | 34 |  | | 19 | 4 |  | 21 | 9-10 |  | 0 |
| Wu Y et al. Mayo76 | China | 13 | 31 | 22 | 37 | | 13 | 13 |  | 6 | 9-10 |  | 0 |
| Xia H et al. Mayo77 | China, Cruz Roja de Wuhan | 1 | 27 | 31 | 0 | | 1 | 0 |  | 1 | 10 |  |  |
| Xiong X et al. Abril78 | China, YouAn, Beijing | 1 | 25 | 33 | 39 | | 1 | 0 |  | 1 | 10 |  | 0 |
| Yan J et al. Abril79 | China, 25 hospitales de Hubei y otras | 116 | 31 | 38 | 38 | | 65 | 51 |  | Sin datos neonatales | | | |
| Yang H et al. Mayo80 | China, Tongji | 27 | 30 |  | 38 | | 19 | 8 |  | 28 | 7-10 | 1 | 1 |
| Yang P et al. Abril81 | China, Zhongnan | 7 |  | 37 | 37 | | 7 | 0 |  | 7 | 8 |  | 0 |
| Yu N et al. Marzo82 | China, Tongji | 7 | 32 | 39 | 39 | | 7 | 0 |  | 7 | 9-10 | 2 | 0 |
| Yu Y et al. Abril83 | China, Hubei | 10 | 30 | 38 | 38 | | 10 | 10 |  | 1 |  |  |  |
| Zeng Y et al. Mayo84 | China, Wuhan | 16 | 31 | 37 | 38 | | 16 | 0 |  | 16 | 7-10 |  | 0 |
| Zhang ZJ. Abril85 | China | Sin datos maternos | | | | | | |  | 4 |  | 7 | 0 |
| Zhu H et al. Febrero86 | China, 5 hospitales de Hubei | 9 | 28 | 35 | 34 | | 9 | 0 |  | 10 | 8-9 |  | 0 |

Abreviaturas:Dx: diagnóstico; lab: laboratorio; min-5,a los 5 minutos de vida; SDG: semanas de gestación. Los espacios vacíos indican datos no reportados en los artículos.

a Estudio de casos y controles; b estudio de cohorte, cohorte retrospectiva o estudio prospectivo. El resto de los artículos fueron reporte de caso o series de casos.

**Suplemento-4. Razones de momios (RM) estimadas a partir de los resultados de nueve estudios con grupo de comparación.**

| **Autor, país (publicados en 2020)** | **RM (IC95%)** | **n Casos** | **n**  **Controles** | **Grupo de comparación** | **Detalles del estudio** |
| --- | --- | --- | --- | --- | --- |
| **Li N et al.,44 China** |  | 36 | 121 (2020); 121 (2019) | Grupo 1: hospitalizadas sin neumonía, mismo periodo que casos (2020).  Grupo 2: embarazadas hospitalizadas, mismo periodo de estudio 2019. (*RM estimadas con controles del 2019)* | Hospital de tercer nivel en Wuhan (24/enero-29/febrero). Casos: 16 SARS-CoV-2 (+) y 18 con Dx clínico.  Grupo 2: 24/enero-11/febrero/2019 para controlar por el estrés ocasionado por la epidemia. Edades: 25-35 años. |
| Bajo peso al nacer | 6.8 (1.2, 45.4) |
| Sufrimiento fetal | 1.9 (0.3, 9.2) |
| Complicacionesa | 6.7 (2.7, 17.2) |
| **Liao J et al.,46 China** |  | 10 | 50 | Embarazadas, hospitalizadas sin COVID-19, con parto vaginal. | Hospital universitario de Wuhan (20/enero-2/marzo). Todas dieron a luz por parto vaginal. Embarazadas con COVID-19; 27-36 años; embarazadas sin COVID-19: 21-37 años. |
| Líquido amniótico contaminado | 0.9 (0.1, 5.2) |
| **Shanes ED et al.,68 EUA** |  | 15 | Históricos: 17,479; con melanoma: 215 | Grupo 1: históricos con indicación clínica de examen patológico de placenta. Grupo 2: con melanoma. Ambos grupos con placentas disponibles con evaluación de patología.(RM estimadas con el grupo 2, melanomas) | Hospital de Chicago (18/marzo-5/mayo).  Grupo 1: 1/enero/2011-30/junio/2018, con indicación clínica de examen patológico de placenta por complicaciones maternas y fetales, productos únicos del tercer trimestre.  Grupo 2: placentas de embarazadas con melanoma debido a la indicación de examen placentario en todas. Edad de los casos: 23-41 años |
| RN pequeño para la edad gestacional | 1.2 (0.3, 4.1) |
| Malaperfusion vascular placentaria - Materna | 7.3 (2.0, 32.2) |
| Malaperfusion vascular placentaria - Fetal | 3.1 (0.8, 17.6) |
| **Pierce-Williams RAM et al.,62 EUA** |  | 20 | 44 | Hospitalizadas con COVID-19 no crítico/severo. | Hospitalizadas en 12 instituciones, EUA (5/marzo-20/abril). Los casos severos se definieron a partir de la falla respiratoria, choque séptico y/o disfunción o falla orgánica múltiple. Media de edad: casos 32 (DE=6); controles 35.9 (DE=4.3) años. |
| Parto indicado por salud materna | 7.2 (1.9, 27.7) |
| **Collin J et al.,17 Suecia** |  | 13 |  | Mujeres no embarazadas en edad reproductiva (n=1’576,651). Denominador de casos: embarazadas en el mismo periodo que los casos (n=95,089). | Datos del Registro Sueco de Cuidados Intensivos; identificaron mujeres en edad reproductiva embarazadas y no embarazadas con SARS-CoV-2 admitidas en la UCI (19/marzo-20/abril). Edad: 20-45 años. |
| **Blitz MJ et al.,7 EUA** |  | 82 | 332 | Mujeres no embarazadas en edad reproductiva, hospitalizadas, con Dx de COVID-19. | 7-hospitales de Nueva York (2/marzo-9/abril). Admisiones a la UCI de embarazadas con COVID-19 y mujeres en edad reproductiva con COVID-19 no embarazadas (15-49 años). |
| **Qiancheng X et al.,64 China** |  | 28 | 54 | Mujeres no embarazadas en edad reproductiva, hospitalizadas, con SARS-CoV-2. | Hospital Central de Wuhan (15/enero-15/marzo). Dx de COVID-19 por RT-PCR o presencia de anticuerpos IgM específicos para SARS-CoV-2. Edad: 18-41 años. |
| **Savasi VM et al.,66 Italia** |  | 14 | 63 | Hospitalizadas con SARS-CoV-2 no severo. | 12 hospitales de maternidad de Italia (23/febrero-28/marzo). Los casos severos se definieron como aquellas que requirieron atención urgente de parto por deterioro de la función respiratoria, admisión a UCI o UCI intermedia durante embarazo o post-pasto. Edad: 15-48; edad de casos severos: 18-40 años. |
| **London V et al.,51 EUA** | | 46 | 22 | Hospitalizadas asintomáticas con COVID-19. | Hospital de tercer nivel de Nueva York (15/marzo-15/abril). Los controles fueron aquellas asintomáticas durante su admisión. Edad: sintomáticas 25.3-33.8; asintomáticas: 24.5-34.8 años. |

Abreviaturas: DE, desviación estándar; EUA, Estados Unidos de América; RN, recién nacido; Dx, diagnóstico; UCI, unidad de cuidados intensivos

a Complicaciones del embarazo: diabetes gestacional, ruptura prematura de membranas, hipertensión gestacional, hipotiroidismo, preeclampsia y taquicardia sinusal.

**Suplemento 5. Proporciones combinadasa de varios eventos maternos reportados en mujeres embarazadas infectadas por SARS-CoV-2 en 79/86 estudios (N=1,042 embarazadas).**

|  | **Estudios con** **n>1** **(45/79)** | | | |  |  | **Estudios con n=1 (34/79)** | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Eventos maternos** | **País** | **n** | **Proporciones (IC95%)** | **Peso %** | **I2 %** |  | **Estudio** | **País** |
| ***Complicaciones asociadas al COVID-19*** | | | | | | | | |
| **Ventilación mecánica** |  |  |  |  |  |  |  |  |
| Breslin N | EUA | 43 | 0.05 (0.01, 0.16) | 10.2 |  |  | Alzamora MC | Perú |
| Cooke WR | Reino Unido | 2 | 1.00 (0.16, 1.00) | 3.6 |  |  | Blauvelt CA | EUA |
| Govind A | Reino Unido | 9 | 0.11 (0.00, 0.48) | 7.3 |  |  | Hong L | EUA |
| Hantoushzadeh S | Irán | 9 | 0.89 (0.52, 1.00) | 7.3 |  |  | Karami P | Irán |
| Hirshberg A | EUA | 5 | 1.00 (0.48, 1.00) | 5.8 |  |  | Kelly JC | EUA |
| Juusela A | EUA | 2 | 0.50 (0.01, 0.99) | 3.6 |  |  | Li J | China |
| Khan S | China | 17 | 0.06 (0.00, 0.29) | 8.8 |  |  | Mehta H | EUA |
| Lokken EM | EUA | 46 | 0.02 (0.00, 0.12) | 10.3 |  |  | Schnettler WT | EUA |
| London V | EUA | 68 | 0.01 (0.00, 0.08) | 10.7 |  |  | Vallejo V | EUA |
| Pierce-Williams RAM | EUA | 64 | 0.05 (0.01, 0.13) | 10.6 |  |  |  |  |
| Savasi VM | Italia | 77 | 0.04 (0.01, 0.11) | 10.8 |  |  |  |  |
| Yan J | China | 116 | 0.02 (0.00, 0.06) | 11 |  |  |  |  |
| ***% combinado*** |  | **458** | **0.12 (0.03, 0.25)** | **100** | **86.8** |  |  |  |
| **Coagulopatías** |  |  |  |  |  |  |  |  |
| Hirshberg A | EUA | 5 | 0.20 (0.01, 0.72) | 9.1 |  |  | Ahmed I | Reino Unido |
| Pereira A | España | 60 | 0.03 (0.00, 0.12) | 35.8 |  |  | Anderson J | EUA |
| Sun M | China | 3 | 0.33 (0.01, 0.91) | 6.2 |  |  | Hong L | EUA |
| Vlachodimitropoulou KE | Canadá/Francia | 2 | 0.50 (0.01, 0.99) | 4.6 |  |  | Khodamoradi Z | Irán |
| Wu Y | China | 13 | 0.08 (0.00, 0.36) | 17.8 |  |  | Martinelli I | Italia |
| Yang H | China | 27 | 0.11 (0.02, 0.29) | 26.5 |  |  | Schnettler WT | EUA |
| ***% combinado*** |  | **110** | **0.06 (0.00, 0.17)** | **100** | **36.7** |  | Taghizadieh A | Irán |
| **Lesión renal aguda** | |  |  |  |  |  |  |  |
| Breslin N | EUA | 43 | 0.02 (0.00, 0.12) | 65.4 |  |  | Karami P | Irán |
| Hantoushzadeh S | Irán | 9 | 0.11 (0.00, 0.48) | 14.3 |  |  | Taghizadieh A | Irán |
| Wu Y | China | 13 | 0.08 (0.00, 0.36) | 20.3 |  |  | Vallejo V | EUA |
| ***% combinado*** |  | **65** | **0.03 (0.00 , 0.10)** | **100** | **<30.0** |  |  |  |
| **Falla orgánica múltiple** |  |  |  |  |  |  |  |  |
| Breslin N | EUA | 43 | 0.02 (0.00, 0.12) | 82.1 |  |  | Karami P | Irán |
| Hantoushzadeh | Irán | 9 | 0.33 (0.07, 0.70) | 17.9 |  |  | Li J | China |
| ***% combinado*** |  | **52** | **0.04 (0.00, 0.13)** | **100** | **<30.0** |  | Vallejo V | EUA |
| **Otra complicación** |  |  |  |  |  |  |  |  |
| Hirshberg A | EUA | 5 | 0.20 (0.01, 0.72) |  |  |  | Karami P | Irán |
| Juusela A | EUA | 2 | 0.50 (0.01, 0.99) |  |  |  |  |  |
| Wu X | China | 23 | 0.13 (0.03, 0.34) |  |  |  |  |  |
| ***% combinado*** |  | **30** | **0.12 (0.01, 0.30)** | **100** | **<30.0** |  |  |  |
| **Muerte materna** |  |  |  |  |  |  |  |  |
| Hantoushzadeh S | Irán | 9 | 0.78 (0.40, 0.97) | 76 |  |  | Karami P | Irán |
|  |  |  |  |  |  |  | Vallejo V | EUA |
| **Admisión a la Unidad de Cuidados Intensivos** | |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  | Ahmed I | Reino Unido |
|  |  |  |  |  |  |  | Anderson J | EUA |
|  |  |  |  |  |  |  | Hong L | EUA |
|  |  |  |  |  |  |  | Karami P | Irán |
|  |  |  |  |  |  |  | Kelly JC | EUA |
|  |  |  |  |  |  |  | Li J | China |
|  |  |  |  |  |  |  | Mehta H | EUA |
|  |  |  |  |  |  |  | Schnettler WT | EUA |
|  |  |  |  |  |  |  | Vallejo V | EUA |
| ***Complicaciones en embarazo y post-parto*** | | | | | | | | |
| **Diabetes gestacional** |  |  |  |  |  |  |  |  |
| Cao D | China | 10 | 0.10 (0.00, 0.45) | 2.3 |  |  | Alzamora MC | Perú |
| Chen R | China | 17 | 0.12 (0.01, 0.36) | 3.8 |  |  | Anderson J | EUA |
| Chen S | China | 5 | 0.40 (0.05, 0.85) | 1.2 |  |  | Gidlöf S | Suecia |
| Cooke WR | Reino Unido | 2 | 0.50 (0.01, 0.99) | 0.6 |  |  |  |  |
| Dória M | Portugal | 12 | 0.08 (0.00, 0.38) | 2.7 |  |  |  |  |
| Ferrazzi E | Italia | 42 | 0.14 (0.05, 0.29) | 9.3 |  |  |  |  |
| Hantoushzadeh S | Irán | 9 | 0.11 (0.00, 0.48) | 2.1 |  |  |  |  |
| Li N | China | 34 | 0.09 (0.02, 0.24) | 7.6 |  |  |  |  |
| Lokken EM | EUA | 46 | 0.04 (0.01, 0.15) | 10.2 |  |  |  |  |
| London V | EUA | 68 | 0.10 (0.04, 0.20) | 15 |  |  |  |  |
| Perrone S | Italia | 4 | 0.25 (0.01, 0.80) | 1 |  |  |  |  |
| Qiancheng X | China | 28 | 0.04 (0.00, 0.18) | 6.2 |  |  |  |  |
| Shanes ED | EUA | 16 | 0.07 (0.00, 0.32) | 3.6 |  |  |  |  |
| Vlachodimitropoulou KE | Canadá/Francia | 2 | 0.50 (0.01, 0.99) | 0.6 |  |  |  |  |
| Yan J | China | 116 | 0.08 (0.04, 0.14) | 25.5 |  |  |  |  |
| Yang H | China | 27 | 0.11 (0.02, 0.29) | 6 |  |  |  |  |
| Yu Y | China | 10 | 0.30 (0.07, 0.65) | 2.3 |  |  |  |  |
| ***% combinado*** |  | **448** | **0.06 (0.04, 0.10)** | **100** | **<30.0** |  |  |  |
| **Sufrimiento fetal** |  |  |  |  |  |  |  |  |
| Breslin N | EUA | 43 | 0.02 (0.00, 0.12) | 9.2 |  |  | Ahmed I | Reino Unido |
| Buonsenso D | Italia | 4 | 0.25 (0.01, 0.81) | 2.8 |  |  | Baud D | Suiza |
| Cao D | China | 10 | 0.20 (0.03, 0.56) | 5 |  |  | Du Y | China |
| Chen R | China | 17 | 0.18 (0.04, 0.43) | 6.6 |  |  | Lang GJ | China |
| Chen S | China | 5 | 0.20 (0.01, 0.72) | 3.2 |  |  | Li J | China |
| Hantoushzadeh S | Irán | 9 | 0.11 (0.00, 0.48) | 4.7 |  |  | Li Y | China |
| Li N | China | 34 | 0.09 (0.02, 0.24) | 8.6 |  |  | Xia H | China |
| Lokken EM | EUA | 46 | 0.07 (0.01, 0.18) | 9.3 |  |  |  |  |
| London V. Mayo | EUA | 68 | 0.01 (0.00, 0.08) | 10.1 |  |  |  |  |
| Wu C | China | 8 | 0.13 (0.00, 0.53) | 4.4 |  |  |  |  |
| Wu X | China | 23 | 0.04 (0.00, 0.22) | 7.5 |  |  |  |  |
| Yan J | China | 116 | 0.08 (0.04, 0.14) | 11 |  |  |  |  |
| Yang H | China | 27 | 0.11 (0.02, 0.29) | 7.9 |  |  |  |  |
| Yu Y | China | 10 | 0.40 (0.12, 0.74) | 5 |  |  |  |  |
| Zhu H | China | 9 | 0.67 (0.30, 0.93) | 4.7 |  |  |  |  |
| ***% combinado*** |  | **429** | **0.10 (0.05, 0.17)** | **100** | **63.3** |  |  |  |
| **Ruptura prematura de membranas** | |  |  |  |  |  |  |  |
| Cao D | China | 10 | 0.40 (0.12 , 0.74) | 4.1 |  |  | Lyra J | Portugal |
| Dória M | Portugal | 12 | 0.08 (0.00, 0.38) | 4.6 |  |  | Xiong X | China |
| Hantoushzadeh S | Irán | 9 | 0.11 (0.00, 0.48) | 3.8 |  |  |  |  |
| Khan S | China | 17 | 0.06 (0.00, 0.29) | 5.7 |  |  |  |  |
| Li N | China | 34 | 0.06 (0.01, 0.20) | 8 |  |  |  |  |
| Liu W | China | 19 | 0.16 (0.03, 0.40) | 6.1 |  |  |  |  |
| Pierce-Williams RAM | EUA | 64 | 0.02 (0.00, 0.08) | 9.9 |  |  |  |  |
| Qadri F | EUA | 16 | 0.13 (0.02, 0.38) | 5.5 |  |  |  |  |
| Shanes ED | EUA | 16 | 0.07 (0.00, 0.32) | 5.5 |  |  |  |  |
| Wu C | China | 8 | 0.25 (0.03, 0.65) | 3.5 |  |  |  |  |
| Wu X | China | 23 | 0.09 (0.01, 0.28) | 6.7 |  |  |  |  |
| Wu Y | China | 13 | 0.08 (0.00, 0.36) | 4.9 |  |  |  |  |
| Yan J | China | 116 | 0.05 (0.02, 0.11) | 11.2 |  |  |  |  |
| Yang H | China | 27 | 0.11 (0.02, 0.29) | 7.2 |  |  |  |  |
| Yu Y | China | 10 | 0.40 (0.12, 0.74) | 4.1 |  |  |  |  |
| Zeng Y | China | 16 | 0.19 (0.04, 0.46) | 5.5 |  |  |  |  |
| Zhu H | China | 9 | 0.33 (0.07, 0.70) | 3.8 |  |  |  |  |
| ***% combinado*** |  | **419** | **0.10 (0.06, 0.16)** | **100** | **49.1** |  |  |  |
| **Preeclampsia** |  |  |  |  |  |  |  |  |
| Baergen RN | EUA | 20 | 0.10 (0.01, 0.32) | 6.9 |  |  | Gidlöf S | Suecia |
| Cao D | China | 10 | 0.30 (0.07, 0.65) | 4.2 |  |  |  |  |
| Chen S | China | 5 | 0.20 (0.01, 0.72) | 2.4 |  |  |  |  |
| Juusela A | EUA | 2 | 0.50 (0.01, 0.99) | 1.1 |  |  |  |  |
| Li N | China | 34 | 0.03 (0.00, 0.15) | 9.7 |  |  |  |  |
| London V | EUA | 68 | 0.06 (0.02, 0.14) | 13.7 |  |  |  |  |
| Pereira A | España | 60 | 0.05 (0.01, 0.14) | 13 |  |  |  |  |
| Pierce-Williams RAM | EUA | 64 | 0.02 (0.00, 0.08) | 13.3 |  |  |  |  |
| Wu C | China | 8 | 0.13 (0.00, 0.53) | 3.5 |  |  |  |  |
| Yan J | China | 116 | 0.03 (0.01, 0.09) | 16.5 |  |  |  |  |
| Yang H | China | 27 | 0.04 (0.00, 0.19) | 8.5 |  |  |  |  |
| Yang P | China | 7 | 0.29 (0.04, 0.71) | 3.1 |  |  |  |  |
| Yu Y | China | 10 | 0.10 (0.00, 0.45) | 4.2 |  |  |  |  |
| ***% combinado*** |  | **431** | **0.04 (0.01, 0.08)** | **100** | **38.9** |  |  |  |
| **Trastornos hipertensivos excluyendo preeclampsia** | | | | | | | | |
| Breslin N | EUA | 43 | 0.02 (0.00, 0.12) | 10.7 |  |  |  |  |
| Chen R | China | 17 | 0.06 (0.00, 0.29) | 5.4 |  |  |  |  |
| Dória M | Portugal | 12 | 0.08 (0.00, 0.38) | 4.1 |  |  |  |  |
| Li N | China | 34 | 0.09 (0.02, 0.24) | 9.2 |  |  |  |  |
| Lokken EM | EUA | 46 | 0.02 (0.00, 0.12) | 11.2 |  |  |  |  |
| Pierce-Williams RAM | EUA | 64 | 0.03 (0.00, 0.11) | 13.6 |  |  |  |  |
| Qiancheng X | China | 28 | 0.04 (0.00, 0.18) | 8 |  |  |  |  |
| Shanes ED | EUA | 16 | 0.07 (0.00, 0.32) | 5.2 |  |  |  |  |
| Wu X | China | 23 | 0.17 (0.05, 0.39) | 6.9 |  |  |  |  |
| Yan J | China | 116 | 0.01 (0.00, 0.05) | 18.1 |  |  |  |  |
| Yang H | China | 27 | 0.07 (0.01, 0.24) | 7.8 |  |  |  |  |
| ***% combinado*** |  | **426** | **0.04 (0.01, 0.07)** | **100** | **31.5** |  |  |  |
| **Trabajo de parto prematuro espontáneo** | | | | | | | | |
| Baergen RN | EUA | 20 | 0.05 (0.00, 0.25) | 12.3 |  |  | Browne PC | EUA |
| Ferrazzi E | Italia | 42 | 0.12 (0.04, 0.26) | 25.5 |  |  |  |  |
| Hantoushzadeh S | Irán | 9 | 0.11 (0.00, 0.48) | 5.7 |  |  |  |  |
| Pierce-Williams RAM | EUA | 64 | 0.03 (0.00, 0.11) | 38.6 |  |  |  |  |
| Qadri F | EUA | 16 | 0.06 (0.00, 0.30) | 9.9 |  |  |  |  |
| Wu Y | China | 13 | 0.08 (0.00, 0.36) | 8.1 |  |  |  |  |
| ***% combinado*** |  | **164** | **0.05 (0.02, 0.10)** | **100** | **<30.0** |  |  |  |
| **Desprendimiento de placenta** |  |  |  |  |  |  |  |  |
| Cao D | China | 10 | 0.10 (0.00, 0.45) | 18.9 |  |  | Kuhrt K | Reino Unido |
| Li N | China | 34 | 0.06 (0.01, 0.20) | 62.2 |  |  |  |  |
| Yu Y | China | 10 | 0.10 (0.00, 0.45) | 18.9 |  |  |  |  |
| ***% combinado*** |  | **54** | **0.06 (0.04, 0.10)** | **100** | **<30.0** |  |  |  |
| **Polihidramnios/Oligohidramnios** |  |  |  |  |  |  |  |  |
| Pierce-Williams RAM | EUA | 64 | 0.02 (0.00, 0.08) | 45.9 |  |  | Ahmed I | Reino Unido |
| Zeng Y | China | 16 | 0.06 (0.00, 0.30) | 30.8 |  |  |  |  |
| Zhu H | China | 9 | 0.11 (0.00, 0.48) | 23.3 |  |  |  |  |
| ***% combinado*** |  | **89** | **0.05 (0.00, 0.20)** | **100** | **60.8** |  |  |  |
| **Placenta previa** |  |  |  |  |  |  |  |  |
| Baergen RN. Mayo, 2020 | EUA | 20 | 0.05 (0.00, 0.25) | 37.3 |  |  |  |  |
| Li N | China | 34 | 0.03 (0.00, 0.15) | 62.7 |  |  |  |  |
| ***% combinado*** |  | **54** | **0.04 (0.00, 0.11)** | **100** | **<30.0** |  |  |  |
| **Otras complicaciones del embarazob** | | | | | | | | |
| Breslin N | EUA | 43 | 0.05(0.01 , 0.16) | 9.9 |  |  | Alzamora MC | Perú |
| Cao D | China | 10 | 0.10 (0.00, 0.45) | 6.4 |  |  | Browne PC | EUA |
| Fan C | China | 2 | 0.50 (0.01, 0.99) | 2.6 |  |  | Kalafat E | Turquía |
| Khan S | China | 17 | 0.29 (0.10, 0.56) | 7.9 |  |  | Karami P | Irán |
| Li N | China | 34 | 0.12 (0.03, 0.27) | 9.5 |  |  | Kuhrt K | Reino Unido |
| Liu W | China | 19 | 0.05 (0.00, 0.26) | 8.2 |  |  | Lee DH | Corea |
| Lokken EM | EUA | 46 | 0.02 (0.00, 0.12) | 10.1 |  |  |  |  |
| Pereira A | España | 60 | 0.02 (0.00 , 0.09) | 10.5 |  |  |  |  |
| Vlachodimitropoulou KE | Canadá/Francia | 2 | 1.00 (0.16, 1.00) | 2.6 |  |  |  |  |
| Wu X | China | 23 | 0.17 (0.05, 0.39) | 8.7 |  |  |  |  |
| Yan J | China | 116 | 0.01 (0.00, 0.05) | 11.2 |  |  |  |  |
| Yu Y | China | 10 | 0.10 (0.00, 0.45) | 6.4 |  |  |  |  |
| Zhu H | China | 9 | 0.44 (0.14, 0.79) | 6.1 |  |  |  |  |
| ***% combinado*** |  | **391** | **0.08 (0.02, 0.17)** | **100** | **75.4** |  |  |  |
| **Complicación en el post-partoc** |  |  |  |  |  |  |  |  |
| Breslin N | EUA | 43 | 0.02 (0.00, 0.12) | 19.4 |  |  | Vallejo V | EUA |
| Buonsenso D | Italia | 4 | 0.50 (0.07, 0.93) | 15.3 |  |  |  |  |
| Liao J | China | 10 | 1.00 (0.69, 1.00) | 17.7 |  |  |  |  |
| London V | EUA | 68 | 0.03 (0.00, 0.10) | 19.6 |  |  |  |  |
| Perrone S | Italia | 4 | 0.25 (0.01, 0.81) | 15.3 |  |  |  |  |
| Vlachodimitropoulou KE | Canadá/Francia | 2 | 0.50 (0.01, 0.99) | 12.9 |  |  |  |  |
| ***% combinado*** |  | **131** | **0.32 (0.01, 0.75)** | **100** | **92.4** |  |  |  |
|  |  |  |  |  |  |  |  |  |
| ***Enfermedades pre-existentes*** |  |  |  |  |  |  |  |  |
| **Obesidad** |  |  |  |  |  |  |  |  |
| Breslin N | EUA | 43 | 0.60 (0.44, 0.75) | 15.2 |  |  | Ahmed I | Reino Unido |
| Cooke WR | Reino Unido | 2 | 0.50 (0.01, 0.99) | 6.4 |  |  | Anderson J | EUA |
| Hantoushzadeh S | Irán | 9 | 0.22 (0.03. 0.60) | 11.7 |  |  | Baud D | Suiza |
| Hirshberg A | EUA | 5 | 0.40 (0.05, 0.85) | 9.6 |  |  | Gidlöf S | Suecia |
| Juusela A | EUA | 2 | 0.50 (0.01, 0.99) | 6.4 |  |  | Hong L | EUA |
| Lokken EM | EUA | 46 | 0.33 (0.20, 0.48) | 15.3 |  |  | Kelly JC | EUA |
| Qadri F | EUA | 16 | 0.63 (0.35, 0.85) | 13.4 |  |  | Martinelli I | Italia |
| Savasi VM | Italia | 77 | 0.09 (0.04, 0.18) | 15.8 |  |  |  |  |
| Vlachodimitropoulou KE | Canadá/Francia | 2 | 0.50 (0.01, 0.99) | 6.4 |  |  |  |  |
| ***% combinado*** |  | **202** | **0.37 (0.16, 0.61)** | **100** | **83** |  |  |  |
| **Hipotiroidismo** |  |  |  |  |  |  |  |  |
| Baergen RN | EUA | 20 | 0.05 (0.00, 0.25) | 8 |  |  | Hong L | EUA |
| Cao D | China | 10 | 0.10 (0.00, 0.45) | 4.1 |  |  |  |  |
| Hantoushzadeh S | Irán | 9 | 0.11 (0.00, 0.48) | 3.7 |  |  |  |  |
| Li N | China | 34 | 0.03 (0.00, 0.15) | 13.5 |  |  |  |  |
| Lokken EM | EUA | 46 | 0.07 (0.01, 0.18) | 18.1 |  |  |  |  |
| Perrone S | Italia | 4 | 0.50 (0.07, 0.93) | 1.8 |  |  |  |  |
| Qadri F | EUA | 16 | 0.06 (0.00. 0.30) | 6.4 |  |  |  |  |
| Qiancheng X | China | 28 | 0.04 (0.00, 0.18) | 11.1 |  |  |  |  |
| Wu X | China | 23 | 0.09 (0.01, 0.28) | 9.2 |  |  |  |  |
| Yang H | China | 27 | 0.07 (0.01, 0.24) | 10.7 |  |  |  |  |
| Yu N | China | 7 | 0.14 (0.00, 0.58) | 2.9 |  |  |  |  |
| Yu Y | China | 10 | 0.10 (0.00, 0.45) | 4.1 |  |  |  |  |
| Zeng Y | China | 16 | 0.13 (0.02, 0.38) | 6.4 |  |  |  |  |
| ***% combinado*** |  | **250** | **0.06 (0.03, 0.10)** | **100** | **<30.0** |  |  |  |
| **Asma** |  |  |  |  |  |  |  |  |
| Breslin N | EUA | 43 | 0.19 (0.08, 0.33) | 13.8 |  |  | Ahmed I | Reino Unido |
| Dória M | Portugal | 12 | 0.08 (0.00, 0.38) | 9.4 |  |  | Anderson J | EUA |
| Govind A | Reino Unido | 9 | 0.11 (0.00, 0.48) | 2 |  |  | Browne PC | EUA |
| Hirshberg A | EUA | 5 | 0.20 (0.01, 0.72) | 5.7 |  |  |  |  |
| Lokken EM | EUA | 46 | 0.09 (0.02, 0.21) | 14 |  |  |  |  |
| London V | EUA | 68 | 0.03 (0.00, 0.10) | 15 |  |  |  |  |
| Pierce-Williams RAM | EUA | 64 | 0.25 (0.15, 0.37) | 14.8 |  |  |  |  |
| Shanes ED | EUA | 16 | 0.13 (0.02, 0.38) | 10.3 |  |  |  |  |
| Vlachodimitropoulou KE | Canadá/Francia | 2 | 0.50 (0.01, 0.99) | 3.2 |  |  |  |  |
| ***% combinado*** |  | **265** | **0.11 (0.04, 0.20)** | **100** | **58.7** |  |  |  |
| **Diabetes tipo 2** |  |  |  |  |  |  |  |  |
| Baergen RN | EUA | 20 | 0.05 (0.00, 0.25) | 10.3 |  |  | Ahmed I | Reino Unido |
| Breslin N | EUA | 43 | 0.07 (0.01, 0.19) | 21.9 |  |  | Alzamora MC | Perú |
| Cooke WR | Reino Unido | 2 | 0.50 (0.01, 0.99) | 1.3 |  |  | Anderson J | EUA |
| Govind A | Reino Unido | 9 | 0.11 (0.00, 0.48) | 4.8 |  |  |  |  |
| Hirshberg A | EUA | 5 | 0.20 (0.01, 0.72) | 2.8 |  |  |  |  |
| Juusela A | EUA | 2 | 0.50 (0.01, 0.99) | 1.3 |  |  |  |  |
| Lokken EM | EUA | 46 | 0.04 (0.01, 0.15) | 23.4 |  |  |  |  |
| London V | EUA | 68 | 0.10 (0.04, 0.20) | 34.4 |  |  |  |  |
| ***% combinado*** |  | **195** | **0.04 (0.01, 0.08)** | **100** | **<30.0** |  |  |  |
| **Hipertensión arterial crónica** |  |  |  |  |  |  |  |  |
| Baergen RN | EUA | 20 | 0.05 (0.00, 0.25) | 8.2 |  |  |  |  |
| Breslin N | EUA | 43 | 0.07 (0.01, 0.19) | 12 |  |  |  |  |
| Dória M | Portugal | 12 | 0.08 (0.00, 0.38) | 5.9 |  |  |  |  |
| Govind A | Reino Unido | 9 | 0.11 (0.00, 0.48) | 4.9 |  |  |  |  |
| Hirshberg A | EUA | 5 | 0.40 (0.05, 0.85) | 3.1 |  |  |  |  |
| Li N | China | 34 | 0.03 (0.00, 0.15) | 10.8 |  |  |  |  |
| Lokken EM | EUA | 46 | 0.04 (0.01, 0.15) | 12.3 |  |  |  |  |
| London V | EUA | 68 | 0.03 (0.00, 0.10) | 14.1 |  |  |  |  |
| Pierce-Williams RAM | EUA | 64 | 0.17 (0.09, 0.29) | 13.9 |  |  |  |  |
| Savasi VM | Italia | 77 | 0.01 (0.00, 0.07) | 14.7 |  |  |  |  |
| ***% combinado*** |  | **378** | **0.05 ( 0.02, 0.10)** | **100** | **54.5** |  |  |  |
| **Otra comorbilidadd** |  |  |  |  |  |  |  |  |
| Baergen RN | EUA | 20 | 0.05 (0.00, 0.25) | 6.5 |  |  | Ahmed I | Reino Unido |
| Breslin N | EUA | 43 | 0.09 (0.03, 0.22) | 8.1 |  |  | Browne PC | EUA |
| Cao D | China | 10 | 0.10 (0.00, 0.45) | 4.8 |  |  | Hong L | EUA |
| Chen R | China | 17 | 0.29 (0.10, 0.56) | 6.1 |  |  | Kalafat E | Turquía |
| Dória M | Portugal | 12 | 0.33 (0.10, 0.65) | 5.2 |  |  | Kuhrt K | Reino Unido |
| Hantoushzadeh S | Irán | 9 | 0.33 (0.07, 0.70) | 4.5 |  |  |  |  |
| Hirshberg A | EUA | 5 | 0.40 (0.05, 0.85) | 3.2 |  |  |  |  |
| Juusela A | EUA | 2 | 1.00 (0.16, 1.00) | 1.7 |  |  |  |  |
| Li N | China | 34 | 0.09 (0.02, 0.24) | 7.7 |  |  |  |  |
| Liu D | China | 15 | 0.13 (0.02, 0.40) | 5.8 |  |  |  |  |
| Qadri F | EUA | 16 | 0.13 (0.02, 0.38) | 5.9 |  |  |  |  |
| Qiancheng X | China | 28 | 0.07 (0.01, 0.24) | 7.3 |  |  |  |  |
| Savasi VM | Italia | 77 | 0.01 (0.00, 0.07) | 9 |  |  |  |  |
| Vlachodimitropoulou KE | Canadá/Francia | 2 | 0.50 (0.01, 0.99) | 1.7 |  |  |  |  |
| Wu X | China | 23 | 0.09 (0.01, 0.28) | 6.8 |  |  |  |  |
| Yang H | China | 27 | 0.11 (0.02, 0.29) | 7.2 |  |  |  |  |
| Yu N | China | 7 | 0.43 (0.10, 0.82) | 3.9 |  |  |  |  |
| Yu Y | China | 10 | 0.10 (0.00, 0.45) | 4.8 |  |  |  |  |
| ***% combinado*** |  | **357** | **0.13 (0.06, 0.20)** | **100** | **60.8** |  |  |  |
| ***Desenlace del embarazo*** |  |  |  |  |  |  |  |  |
| **Cesárea por indicación obstétricae** | | | | | | | | |
| Baergen RN | EUA | 20 | 0.20 (0.06, 0.44) | 4 |  |  | Gidlöf S | Suecia |
| Breslin N | EUA | 43 | 0.19 (0.08, 0.33) | 4.4 |  |  | Kuhrt K | Reino Unido |
| Buonsenso D | Italia | 4 | 0.25 (0.01, 0.81) | 2.6 |  |  | Lang GJ | China |
| Cao D | China | 10 | 0.20 (0.03, 0.56) | 3.5 |  |  | Lee DH | Corea |
| Chen R | China | 17 | 0.18 (0.04, 0.43) | 3.9 |  |  | Li Y | China |
| Chen S | China | 5 | 0.40 (0.05, 0.85) | 2.8 |  |  | Vallejo V | EUA |
| Collin J | Suecia | 13 | 0.15 (0.02, 0.45) | 3.7 |  |  |  |  |
| Ferrazzi E | Italia | 42 | 0.19 (0.09, 0.34) | 4.4 |  |  |  |  |
| Govind A | Reino Unido | 9 | 0.67 (0.30, 0.93) | 3.4 |  |  |  |  |
| Hirshberg A | EUA | 5 | 0.60 (0.15, 0.95) | 2.8 |  |  |  |  |
| Khan S | China | 17 | 0.18 (0.04, 0.43) | 3.9 |  |  |  |  |
| Li N | China | 34 | 0.29 (0.15, 0.47) | 4.3 |  |  |  |  |
| Liu D | China | 15 | 0.67 (0.38, 0.88) | 3.8 |  |  |  |  |
| Lokken EM | EUA | 46 | 0.07 (0.01, 0.18) | 4.4 |  |  |  |  |
| London V | EUA | 68 | 0.01 (0.00, 0.08) | 4.6 |  |  |  |  |
| Pereira A | España | 60 | 0.05 (0.01, 0.14) | 4.5 |  |  |  |  |
| Qadri F | EUA | 16 | 0.06 (0.00, 0.30) | 3.9 |  |  |  |  |
| Vlachodimitropoulou KE | Canadá/Francia | 2 | 1.00 (0.16, 1.00) | 1.9 |  |  |  |  |
| Wu C | China | 8 | 0.75 (0.35, 0.97) | 3.3 |  |  |  |  |
| Wu X | China | 23 | 0.78 (0.56, 0.93) | 4.1 |  |  |  |  |
| Wu Y | EUA | 13 | 0.08 (0.00, 0.36) | 3.7 |  |  |  |  |
| Yan J | China | 116 | 0.45 (0.36, 0.54) | 4.7 |  |  |  |  |
| Yang H | China | 27 | 0.33 (0.17, 0.54) | 4.2 |  |  |  |  |
| Yang P | China | 7 | 0.43 (0.10, 0.82) | 3.1 |  |  |  |  |
| Yu N | China | 7 | 0.57 (0.18, 0.90) | 3.1 |  |  |  |  |
| Yu Y | China | 10 | 0.20 (0.03, 0.56) | 3.5 |  |  |  |  |
| Zhu H | China | 9 | 0.78 (0.40, 0.97) | 3.4 |  |  |  |  |
| ***% combinado*** |  | **646** | **0.30 (0.20, 0.41)** | **100** | **85.4** |  |  |  |
| **Parto vaginal** |  |  |  |  |  |  |  |  |
| Baergen RN | EUA | 20 | 0.75 (0.51, 0.91) | 3.4 |  |  | De Socio GV | Italia |
| Breslin N | EUA | 43 | 0.23 (0.12, 0.39) | 3.8 |  |  | Iqbal SN | EUA |
| Cao D | China | 10 | 0.20 (0.03, 0.56) | 2.8 |  |  | Karami P | Irán |
| Chen S | China | 5 | 0.60 (0.15, 0.95) | 2.1 |  |  | Lowe B | Australia |
| Collin J | Suecia | 13 | 0.38 (0.14, 0.68) | 3 |  |  | Xiong X | China |
| Dória M | Portugal | 12 | 0.33 (0.10, 0.65) | 3 |  |  |  |  |
| Ferrazzi E | Italia | 42 | 0.57 (0.41, 0.72) | 3.8 |  |  |  |  |
| Govind A | Reino Unido | 9 | 0.11 (0.00, 0.48) | 2.7 |  |  |  |  |
| Hantoushzadeh S | Irán | 9 | 0.11 (0.00, 0.48) | 2.7 |  |  |  |  |
| Khan S | China | 3 | 1.00 (0.29, 1.00) | 1.6 |  |  |  |  |
| Li N | China | 34 | 0.06 (0.01, 0.20) | 3.7 |  |  |  |  |
| Liao J | China | 10 | 1.00 (0.69, 1.00) | 2.8 |  |  |  |  |
| Liu D | China | 15 | 0.07 (0.00, 0.32) | 3.2 |  |  |  |  |
| Liu W | China | 19 | 0.05 (0.00, 0.26) | 3.3 |  |  |  |  |
| Lokken EM | EUA | 46 | 0.11 (0.04, 0.24) | 3.9 |  |  |  |  |
| London V | EUA | 68 | 0.50 (0.38, 0.62) | 4 |  |  |  |  |
| Penfield CA | EUA | 11 | 0.36 (0.11, 0.69) | 2.9 |  |  |  |  |
| Pereira A | España | 60 | 0.30 (0.19, 0.43) | 4 |  |  |  |  |
| Perrone S | Italia | 4 | 0.75 (0.19, 0.99) | 1.9 |  |  |  |  |
| Pierce-Williams RAM | EUA | 64 | 1.13 (0.06, 0.23) | 4 |  |  |  |  |
| Qadri F | EUA | 16 | 0.50 (0.25, 0.75) | 3.2 |  |  |  |  |
| Qiancheng X | China | 28 | 0.18 (0.06, 0.37) | 3.6 |  |  |  |  |
| Salvatori G | Italia | 2 | 1.00 (0.16, 1.00) | 1.3 |  |  |  |  |
| Savasi VM | Italia | 77 | 0.29 (0.19, 0.40) | 4 |  |  |  |  |
| Wu C. Abril | China | 8 | 0.25 (0.03, 0.65) | 2.6 |  |  |  |  |
| Wu X . Abril | China | 23 | 0.09 (0.01, 0.28) | 3.5 |  |  |  |  |
| Wu Y | China | 13 | 0.08 (0.00, 0.36) | 3 |  |  |  |  |
| Yan J | China | 116 | 0.12 (0.07, 0.19) | 4.1 |  |  |  |  |
| Yang H | China | 27 | 0.19 (0.06, 0.38) | 3.6 |  |  |  |  |
| Yu Y | China | 10 | 0.20 (0.03, 0.56) | 2.8 |  |  |  |  |
| Zeng Y | China | 16 | 0.25 (0.07, 0.52) | 3.2 |  |  |  |  |
| Zhu H | China | 9 | 0.22 (0.03, 0.60) | 2.7 |  |  |  |  |
| ***% combinado*** |  | **842** | **0.28 (0.20, 0.37)** | **100** | **81.8** |  |  |  |
| **Cesárea electiva** |  |  |  |  |  |  |  |  |
| Baergen RN | EUA | 20 | 0.05 (0.00, 0.25) | 7.2 |  |  | Ahmed I | Reino Unido |
| Buonsenso D | Italia | 4 | 0.25 (0.01; 0.81) | 3.5 |  |  | Khodamoradi Z | Irán |
| Cao D | China | 10 | 0.60 (0.26, 0.88) | 5.6 |  |  |  |  |
| Chen R | China | 17 | 0.35 (0.14, 0.62) | 6.8 |  |  |  |  |
| Collin J | Suecia | 13 | 0.08 (0.00, 0.36) | 6.2 |  |  |  |  |
| Dória M | Portugal | 12 | 0.50 (0.21, 0.79) | 6 |  |  |  |  |
| London V | EUA | 68 | 0.19 (0.11, 0.30) | 9.1 |  |  |  |  |
| Perrone S | EUA | 64 | 0.25 (0.01, 0.81) | 3.5 |  |  |  |  |
| Pierce-Williams RAM | Italia | 4 | 0.38 (0.26, 0.50) | 9 |  |  |  |  |
| Qadri F | EUA | 16 | 0.06 (0.00, 0.30) | 6.7 |  |  |  |  |
| Qiancheng X | China | 28 | 0.61 (0.41, 0.78) | 7.8 |  |  |  |  |
| Savasi VM | Italia | 77 | 0.14 (0.07, 0.24) | 9.2 |  |  |  |  |
| Wu Y | China | 13 | 0.23 (0.05, 0.54) | 6.2 |  |  |  |  |
| Yang H | China | 27 | 0.33 (0.17, 0.54) | 7.8 |  |  |  |  |
| Yu Y | China | 10 | 0.60 (0.26, 0.88) | 5.6 |  |  |  |  |
| ***% combinado*** |  | **383** | **0.28 (0.18, 0.39)** | **100** | **73.4** |  |  |  |
| **Aborto espontáneo** |  |  |  |  |  |  |  |  |
| London V | EUA | 68 | 0.01 (0.00, 0.08) | 34 |  |  | Baud D | Suiza |
| Shanes ED | EUA | 16 | 0.06 (0.00, 0.30) | 8.2 |  |  |  |  |
| Yan J | China | 116 | 0.01 (0.00, 0.05) | 57.8 |  |  |  |  |
| ***% combinado*** |  | **200** | **0.01 (0.00, 0.03)** | **100** | **<30.0** |  |  |  |
| **Interrupción voluntaria de embarazo** |  |  |  |  |  |  |  |  |
| Qiancheng X | China | 28 | 0.14 (0.04, 0.33) | 35.9 |  |  |  |  |
| Wu X | China | 23 | 0.13 (0.03, 0.34) | 29.6 |  |  |  |  |
| Yang H | China | 27 | 0.15 (0.04, 0.34) | 34.6 |  |  |  |  |
| ***% combinado*** |  | **78** | **0.14 (0.07, 0.23)** | **100** | **<30.0** |  |  |  |
| **Cesárea indicada por COVID-19** |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  | Alzamora MC | Perú |
|  |  |  |  |  |  |  | Blauvelt CA | EUA |
|  |  |  |  |  |  |  | Cheb R | China |
|  |  |  |  |  |  |  | Cooke | WR |
|  |  |  |  |  |  |  | Du Y | China |
|  |  |  |  |  |  |  | Kalafat C | Turquía |
|  |  |  |  |  |  |  | Kelly JC | EUA |
|  |  |  |  |  |  |  | Li J | China |
|  |  |  |  |  |  |  | Lu D | China |
|  |  |  |  |  |  |  | Lyra J | Portugal |
|  |  |  |  |  |  |  | Martinelli I | Italia |
|  |  |  |  |  |  |  | Mehta H | EUA |
|  |  |  |  |  |  |  | Penfield | CA |
|  |  |  |  |  |  |  | Peng Z | China |
|  |  |  |  |  |  |  | Schnettler WT | EUA |
|  |  |  |  |  |  |  | Taghizadieh A | Irán |
|  |  |  |  |  |  |  | Xia H | China |

a Los eventos con I2 <30% se estimaron con modelos de efectos fijos y aquellos con I2 ≥30% con modelos de efectos aleatorios. La I2 de Higgings representa el porcentaje de heterogeneidad entre estudios.

b Colestasis del embarazo, síndrome HELLP y otras no especificadas.

c Hemorragia y atonía uterina.

d Colitis ulcerativa, enfermedad renal crónica, apnea de sueño, hiperlipidemia, ovarios poliquísticos, tiroidectomía, hepatitis B crónica, anemia y otras no especificadas.

e Preeclampsia, sufrimiento fetal, ruptura temprana de membranas, diabetes gestacional, desprendimiento de placenta, placenta previa, parto obstruido, parto prolongado, cesárea previa, latido fetal disminuido, embarazo gemelar, entre otras.

**Suplemento 6. Proporciones combinadasa de eventos neonatales basado en 75/86 estudios (N=644 neonatos).**

|  | **Estudios con n>1 (46/75)** | | | | |  | **Estudios con n=1 (29/75)** | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Eventos neonatales** | **País** | **n** | **Proporciones (IC95%)** | **Peso %** | **I2 %** |  | **Estudio** | **Pais** |
| **Apgar ≥7 a los 5 minuto de vida** | | | | | | | | |
| Beargen NR | EUA | 21 | 1.00 (0.84, 1.00) | 3.3 |  |  | Alzamora MC | Perú |
| Breslin N | EUA | 18 | 1.00 (0.81, 1.00) | 3.2 |  |  | Blauvelt CA | EUA |
| Buonsenso D | Italia | 2 | 1.00 (0.16, 1.00) | 1.8 |  |  | De Socio GV | Italia |
| Cao D | China | 11 | 1.00 (0.72, 1.00) | 3 |  |  | Du Y | China |
| Chen H | China | 6 | 1.00 (0.54, 1.00) | 2.6 |  |  | Iqbal SN | EUA |
| Chen R | China | 17 | 1.00 (0.80,1.00) | 3.2 |  |  | Kalafat E | Turquía |
| Chen S | China | 5 | 1.00 (0.48, 1.00) | 2.5 |  |  | Lang GJ | China |
| Cooke WR | Reino Unido | 2 | 0.50 (0.01, 0.99) | 1.8 |  |  | Lorenz N | Alemania |
| Doria M | Portugal | 11 | 1.00 (0.72, 1.00) | 3 |  |  | Lowe B | Australia |
| Fan C | China | 2 | 1.00 (0.16, 1.00) | 1.8 |  |  | Lu D | China |
| Ferrazzi E | Italia | 42 | 0.95 (0.84, 0.99) | 3.5 |  |  | Lyra J | Portugal |
| Gidlöf S | Suecia | 2 | 1.00 (0.16, 1.00) | 1.8 |  |  | Lee DH | Korea |
| Govind A | Reino Unido | 9 | 0.89 (0.52, 1.00) | 2.9 |  |  | Peng Z | China |
| Hantoushzadeh S | Irán | 11 | 0.45 (0.17, 0.77) | 3 |  |  | Vallejo V | EUA |
| Hishberg A | EUA | 3 | 0.67 (0.09, 0.99) | 2.1 |  |  | Xia H | China |
| Khan S | China | 17 | 1.00 (0.80, 1.00) | 3.2 |  |  | Xiong X | China |
| Khan S | China | 3 | 1.00 (0.29, 1.00) | 2.1 |  |  |  |  |
| Kuhrt K | Reino Unido | 2 | 1.00 (0.16, 1.00) | 1.8 |  |  |  |  |
| Li N | China | 36 | 1.00 (0.90, 1.00) | 3.4 |  |  |  |  |
| Liu D | China | 11 | 1.00 (0.72, 1.00) | 3 |  |  |  |  |
| Liu W | China | 19 | 1.00 (0.82, 1.00) | 3.2 |  |  |  |  |
| Perrone S | Italia | 4 | 1.00 (0.40, 1.00) | 2.3 |  |  |  |  |
| Pierce-Williams RAM | EUA | 33 | 1.00 (0.89, 1.00) | 3.4 |  |  |  |  |
| Qadri F | EUA | 12 | 1.00 (0.74, 1.00) | 3.1 |  |  |  |  |
| Qiancheng X | China | 23 | 1.00 (0.85, 1.00) | 3.3 |  |  |  |  |
| Savasi VM | Italia | 57 | 0.18 (0.09, 0.30) | 3.5 |  |  |  |  |
| Shanes ED | EUA | 16 | 1.00 (0.79, 1.00) | 3.2 |  |  |  |  |
| Sun M | China | 3 | 0.67 (0.09, 0.99) | 2.1 |  |  |  |  |
| Vlachodimitropoulou KE | Canadá/Francia | 2 | 0.50 (0.01, 0.99) | 1.8 |  |  |  |  |
| Wu X | China | 21 | 1.00 (0.84, 1.00) | 3.3 |  |  |  |  |
| Wu Y | China | 6 | 0.83 (0.36, 1.00) | 2.6 |  |  |  |  |
| Yang H | China | 28 | 0.86 (0.67, 0.96) | 3.4 |  |  |  |  |
| Yang P | China | 7 | 1.00 (0.59, 1.00) | 2.7 |  |  |  |  |
| Yu N | China | 7 | 1.00 (0.59, 1.00) | 2.7 |  |  |  |  |
| Zeng Y | China | 16 | 1.00 (0.79, 1.00) | 3.2 |  |  |  |  |
| Zhu H | China | 10 | 1.00 (0.69, 1.00) | 3 |  |  |  |  |
| ***% combinado*** |  | **495** | **0.98 (0.90, 1.00)** | **100** | **84.6** |  |  |  |
| **Pretérmino (<37semanas de gestación)** | | | | | | | | |
| Beargen NR | EUA | 21 | 0.24 (0.08, 0.47) | 3.3 |  |  | Alzamora MC | Perú |
| Breslin N | EUA | 18 | 0.06 (0.00, 0.27) | 3.2 |  |  | Ahmed I | Reino Unido |
| Buonsenso D | Italia | 2 | 0.50 (0.01, 0.99) | 1.3 |  |  | Baud D | Suiza |
| Buonsenso D | Italia | 2 | 0.50 (0.01, 0.99) | 1.3 |  |  | Blauvelt Ca | EUA |
| Cao D | China | 11 | 0.36 (0.11, 0.69) | 2.8 |  |  | Chen R | China |
| Chen H | China | 6 | 0.67 (0.22, 0.96) | 2.2 |  |  | Coronado MA | EUA |
| Chen R | China | 17 | 0.18 (0.04, 0.43) | 3.1 |  |  | Kalafat E | Turquía |
| Cooke WR | Reino Unido | 2 | 1.00 (0.16, 1.00) | 1.3 |  |  | Karami P | Irán |
| Fan C | China | 2 | 0.50 (0.01, 0.99) | 1.3 |  |  | Kelly JC | EUA |
| Ferrazzi E | Italia | 42 | 0.17 (0.07, 0.31) | 3.7 |  |  | Lang GJ | China |
| Gidlöf S | Suecia | 2 | 1.00 (0.16, 1.00) | 1.3 |  |  | Li J | China |
| Govind A | Reino Unido | 9 | 0.22 (0.03, 0.60) | 2.6 |  |  | Li Y | China |
| Hantoushzadeh S | Irán | 11 | 0.91 (0.59, 1.00) | 2.8 |  |  | Martinelli I | Italia |
| Hishberg A | EUA | 3 | 1.00 (0.29, 1.00) | 1.6 |  |  | Peng Z | China |
| Khan S | China | 17 | 0.18 (0.04, 0.43) | 3.1 |  |  | Schnettler WT | EUA |
| Khan S | China | 3 | 0.33 (0.01, 0.91) | 1.6 |  |  | Taghizadieh A | Iran |
| Kuhrt K | Reino Unido | 2 | 1.00 (0.16, 1.00) | 1.3 |  |  | Xia H | China |
| Li N | China | 36 | 0.22 (0.10, 0.39) | 3.6 |  |  | Yu Y | China |
| Liao J | China | 10 | 0.10 (0.04, 0.20) | 2.7 |  |  |  |  |
| Liu D | China | 11 | 0.27 (0.06, 0.61) | 2.8 |  |  |  |  |
| Liu W | China | 19 | 0.05 (0.00, 0.26) | 3.2 |  |  |  |  |
| Liu Y | China | 10 | 0.70 (0.35, 0.93) | 2.7 |  |  |  |  |
| Lokken EM | EUA | 8 | 0.13 (0.00, 0.53) | 2.5 |  |  |  |  |
| London V | EUA | 48 | 0.19 (0.09, 0.33) | 3.7 |  |  |  |  |
| Mehta H | EUA | 2 | 1.00 (0.16, 1.00) | 1.3 |  |  |  |  |
| Penfield CA | EUA | 11 | 0.27 (0.06, 0.61) | 2.8 |  |  |  |  |
| Pereira A | España | 23 | 0.09 (0.01, 0.28) | 3.3 |  |  |  |  |
| Pierce-Williams RAM | EUA | 33 | 0.58 (0.39, 0.75) | 3.6 |  |  |  |  |
| Qadri F | EUA | 12 | 0.08 (0.00, 0.38) | 2.9 |  |  |  |  |
| Qiancheng X | China | 23 | 0.04 (0.00, 0.22) | 3.3 |  |  |  |  |
| Savasi VM | Italia | 57 | 0.28 (0.17, 0.42) | 3.8 |  |  |  |  |
| Sun M | China | 3 | 0.67 (0.09, 0.99) | 1.6 |  |  |  |  |
| Vlachodimitropoulou KE | Canadá/Francia | 2 | 1.00 (0.16, 1.00) | 1.3 |  |  |  |  |
| Wu X | China | 21 | 0.10 (0.01, 0.30) | 3.3 |  |  |  |  |
| Wu Y | China | 6 | 0.33 (0.04, 0.78) | 2.2 |  |  |  |  |
| Yang H | China | 28 | 0.04 (0.00, 0.18) | 3.5 |  |  |  |  |
| Yang P | China | 7 | 0.57 (0.18, 0.90) | 2.4 |  |  |  |  |
| Zeng Y | China | 16 | 0.19 (0.04, 0.46) | 3.1 |  |  |  |  |
| Zhu H | China | 10 | 0.60 (0.26, 0.88) | 2.7 |  |  |  |  |
| ***% combinado*** |  | **566** | **0.30 (0.21, 0.39)** | **100** | **72.7** |  |  |  |
| **Sufrimiento fetal** |  |  |  |  |  |  |  |  |
| Breslin N | EUA | 18 | 0.17 (0.04, 0.41) | 7.4 |  |  | Ahmed I | Reino Unido |
| Buonsenso D | Italia | 2 | 0.50 (0.01, 0.99) | 2.4 |  |  | Du Y | China |
| Buonsenso D | Italia | 2 | 0.50(0.01, 0.99) | 2.4 |  |  | Kalafat E | Turquía |
| Cao D | China | 11 | 0.18 (0.02, 0.52) | 6.1 |  |  | Karami P | Irán |
| Chen H | China | 6 | 0.50 (0.12, 0.88) | 4.6 |  |  | Kelly JC | EUA |
| Chen S | China | 5 | 0.20 (0.01, 0.72) | 4.1 |  |  | Lang GJ | China |
| Hantoushzadeh S | Irán | 11 | 0.45 (0.17, 0.77) | 6.1 |  |  | Li J | China |
| Li N | China | 36 | 0.08 (0.02, 0.22) | 8.8 |  |  | Li Y | China |
| Liu Y | China | 10 | 0.30 (0.07, 0.65) | 5.9 |  |  | Lowe B | Australia |
| Lokken EM | EUA | 8 | 0.38 (0.09, 0.76) | 5.3 |  |  | Martinelli I | Italia |
| London V | EUA | 48 | 0.02 (0.00, 0.11) | 9.3 |  |  | Schnettler WT | EUA |
| Pierce-Williams RAM | EUA | 33 | 0.09 (0.02, 0.24) | 8.7 |  |  | Vallejo V | EUA |
| Vlachodimitropoulou KE | Canadá/Francia | 2 | 0.50 (0.01, 0.99) | 2.4 |  |  | Xia H | China |
| Wu X | China | 21 | 0.05 (0.00, 0.24) | 7.7 |  |  |  |  |
| Wu Y | China | 6 | 0.17 (0.00, 0.64) | 4.6 |  |  |  |  |
| Yang H | China | 28 | 0.11 (0.02, 0.28) | 8.4 |  |  |  |  |
| Zhu H | China | 10 | 0.60 (0.26, 0.88) | 5.9 |  |  |  |  |
| ***% combinado*** |  | **257** | **0.30 (0.21, 0.39)** | **100** | **62.0** |  |  |  |
| **Bajo peso al nacer** |  |  |  |  |  |  |  |  |
| Beargen NR | EUA | 21 | 0.14 (0.03, 0.36) | 6.9 |  |  | Blauvelt Ca | EUA |
| Buonsenso D | Italia | 2 | 0.50 (0.01, 0.99) | 2.8 |  |  | Martinelli I | Italia |
| Cao D | China | 11 | 0.18 (0.02, 0.52) | 5.9 |  |  |  |  |
| Chen H | China | 6 | 0.33 (0.04, 0.78) | 4.8 |  |  |  |  |
| Cooke WR | Reino Unido | 2 | 1.00 (0.16, 1.00) | 2.8 |  |  |  |  |
| Doria M | Portugal | 11 | 0.36 (0.11, 0.69) | 5.9 |  |  |  |  |
| Gidlöf S | Suecia | 2 | 0.50 (0.01, 0.99) | 2.8 |  |  |  |  |
| Govind A | Reino Unido | 9 | 0.11 (0.00, 0.48) | 5.5 |  |  |  |  |
| Hantoushzadeh S | Irán | 11 | 0.45 (0.17, 0.77) | 5.9 |  |  |  |  |
| Hishberg A | EUA | 3 | 1.00 (0.29, 1.00) | 3.5 |  |  |  |  |
| Khan S | China | 17 | 0.18 (0.04, 0.43) | 6.6 |  |  |  |  |
| Kuhrt K | Reino Unido | 2 | 1.00 (0.16, 1.00) | 2.8 |  |  |  |  |
| Li N | China | 36 | 0.14 (0.05, 0.29) | 7.4 |  |  |  |  |
| Mehta H | EUA | 2 | 1.00 (0.16, 1.00) | 2.8 |  |  |  |  |
| Perrone S | Italia | 4 | 0.25 (0.01, 0.81) | 4 |  |  |  |  |
| Qiancheng X | China | 23 | 0.04 (0.00, 0.22) | 7 |  |  |  |  |
| Wu Y | China | 6 | 0.17 (0.00, 0.64) | 4.8 |  |  |  |  |
| Yang H | China | 28 | 0.04 (0.00, 0.18) | 7.2 |  |  |  |  |
| Yang P | China | 7 | 0.14 (0.00, 0.58) | 5.1 |  |  |  |  |
| Zhu H | China | 10 | 0.70 (0.35, 0.93) | 5.7 |  |  |  |  |
| ***% combinado*** |  | **213** | **0.29 (0.16, 0.43)** | **100** | **68.1** |  |  |  |
| **Complicaciones placentariasb** | | | | | | | | |
| Beargen NR | EUA | 21 | 0.43 (0.22, 0.66) | 15.5 |  |  | Baud D | Suiza |
| Cao D | China | 11 | 0.09 (0.00, 0.41) | 14.6 |  |  |  |  |
| Kuhrt K | Reino Unido | 2 | 0.50 (0.01, 0.99) | 10 |  |  |  |  |
| Li N | China | 36 | 0.03 (0.00, 0.15) | 15.9 |  |  |  |  |
| Liu D | China | 11 | 0.09 (0.00, 0.41) | 14.6 |  |  |  |  |
| Shanes ED | EUA | 16 | 0.94 (0.70, 1.00) | 15.1 |  |  |  |  |
| Zhu H | China | 10 | 0.10 (0.00, 0.45) | 14.4 |  |  |  |  |
| ***% combinado*** |  | **107** | **0.27 (0.02, 0.61)** | **100** | **90.0** |  |  |  |
| **Transmisión verticalc** |  |  |  |  |  |  |  |  |
| Mehta H | EUA | 2 | 0.50 (0.01, 0.99) | 17.4 |  |  | Alzamora MC | Perú |
| Penfield CA | EUA | 11 | 0.27 (0.06, 0.61) | 37 |  |  |  |  |
| Yang H | China | 28 | 0.04 (0.00, 0.18) | 45.5 |  |  |  |  |
| ***% combinado*** |  | **41** | **0.13 (0.00, 0.48)** | **100** | **65.9** |  |  |  |
| **Neumonía** |  |  |  |  |  |  |  |  |
| Govind A | Reino Unido | 9 | 0.11 (0.00, 0.48) | 24.7 |  |  | Coronado MA | EUA |
| Hantoushzadeh S | Irán | 11 | 0.09 (0.00, 0.41) | 29.9 |  |  | Lorenz N | Alemania |
| Khan S |  | 17 | 0.29 (0.10, 0.56) | 45.5 |  |  |  |  |
| ***% combinado*** |  | **37** | **0.18 (0.06, 0.33)** | **100** | **<30.0** |  |  |  |
| **Aborto espontáneo** |  |  |  |  |  |  |  |  |
| London V | EUA | 48 | 0.02 (0.00, 0.11) | 67.8 |  |  | Baud D | Suiza |
| Shanes ED | EUA | 16 | 0.06 (0.00, 0.30) | 23.1 |  |  |  |  |
| Wu Y | China | 6 | 0.17 (0.00, 0.64) | 9.1 |  |  |  |  |
| ***% combinado*** |  | **70** | 0.02 (0.00, 0.09) | **100** | **<30.0** |  |  |  |
| **Muerte fetal** | --- |  |  |  |  |  |  |  |
| Hantoushzadeh S | Irán | 11 | 0.45 (0.17, 0.77) | 35.8 |  |  | Karami P | Irán |
| Liu Y | China | 10 | 0.10 (0.00, 0.45) | 34.1 |  |  |  |  |
| Lokken EM | EUA | 8 | 0.13 (0.00, 0.53) | 30.2 |  |  |  |  |
| ***% combinado*** |  | **29** | 0.22 (0.04, 0.47) | **100** | **43.9** |  |  |  |
| **Muerte neonatal** |  |  |  |  |  |  |  |  |
| Hantoushzadeh S | Irán | 11 | 0.18 (0.02, 0.52) | 52.3 |  |  | Li J | China |
| Zhu H | China | 10 | 0.10 (0.00, 0.45) | 47.7 |  |  |  |  |
| ***% combinado*** |  | **21** | **0.14 (0.01, 0.34)** | **100** | **<30.0** |  |  |  |
| **SARS-CoV-2 postivos** |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  | Alzamora MC | Peru |
|  |  |  |  |  |  |  | Baud D | Suiza |
|  |  |  |  |  |  |  | Coronado MA | EUA |
|  |  |  |  |  |  |  | Kamali AM | Iran |
|  |  |  |  |  |  |  | Lorenz N | Alemania |

a Los eventos con I2 <30% se estimaron con modelos de efectos fijos y aquellos con I2 ≥30% con modelos de efectos aleatorios. La I2 de Higgings representa el porcentaje de heterogeneidad entre estudios.

b Trombosis placentaria, vellosidades avasculares y fibrina intramural.

c Considera positivos a los artículos que reportan probable transmisión vertical.

**Referencias**

1. Ahmed I, Azhar A, Eltaweel N, Tan BK. First Covid-19 maternal mortality in the UK associated with thrombotic complications. British journal of haematology.2020. 10.1111/bjh.16849

2. Alzamora MC, Paredes T, Caceres D, Webb CM, Valdez LM, La Rosa M. Severe COVID-19 during Pregnancy and Possible Vertical Transmission. American journal of perinatology.2020. 10.1055/s-0040-1710050

3. Anderson J, Schauer J, Bryant S, Graves CR. The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report. Case reports in women's health.2020:e00221. 10.1016/j.crwh.2020.e00221

4. Baergen RN, Heller DS. Placental Pathology in Covid-19 Positive Mothers: Preliminary Findings. Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.2020;23(3):177-180. 10.1177/1093526620925569

5. Baud D, Greub G, Favre G, Gengler C, Jaton K, Dubruc E*, et al.* Second-Trimester Miscarriage in a Pregnant Woman With SARS-CoV-2 Infection. Jama.2020. 10.1001/jama.2020.7233

6. Blauvelt CA, Chiu C, Donovan AL, Prahl M, Shimotake TK, George RB*, et al.* Acute Respiratory Distress Syndrome in a Preterm Pregnant Patient With Coronavirus Disease 2019 (COVID-19). Obstetrics and gynecology.2020. 10.1097/aog.0000000000003949

7. Blitz MJ, Grünebaum A, Tekbali A, Bornstein E, Rochelson B, Nimaroff M*, et al.* Intensive Care Unit Admissions for Pregnant and Non-Pregnant Women with COVID-19. American journal of obstetrics and gynecology.2020. 10.1016/j.ajog.2020.05.004

8. Breslin N, Baptiste C, Gyamfi-Bannerman C, Miller R, Martinez R, Bernstein K*, et al.* COVID-19 infection among asymptomatic and symptomatic pregnant women: Two weeks of confirmed presentations to an affiliated pair of New York City hospitals. American journal of obstetrics & gynecology MFM.2020:100118. 10.1016/j.ajogmf.2020.100118

9. Browne PC, Linfert JB, Perez-Jorge E. Successful Treatment of Preterm Labor in Association with Acute COVID-19 Infection. American journal of perinatology.2020. 10.1055/s-0040-1709993

10. Buonsenso D, Costa S, Sanguinetti M, Cattani P, Posteraro B, Marchetti S*, et al.* Neonatal Late Onset Infection with Severe Acute Respiratory Syndrome Coronavirus 2. American journal of perinatology.2020. 10.1055/s-0040-1710541

11. Buonsenso D, Raffaelli F, Tamburrini E, Biasucci DG, Salvi S, Smargiassi A*, et al.* Clinical role of lung ultrasound for the diagnosis and monitoring of COVID-19 pneumonia in pregnant women. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.2020. 10.1002/uog.22055

12. Cao D, Yin H, Chen J, Tang F, Peng M, Li R*, et al.* Clinical analysis of ten pregnant women with COVID-19 in Wuhan, China: A retrospective study. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.2020;95:294-300. 10.1016/j.ijid.2020.04.047

13. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W*, et al.* Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet (London, England).2020;395(10226):809-815. 10.1016/s0140-6736(20)30360-3

14. Chen R, Zhang Y, Huang L, Cheng BH, Xia ZY, Meng QT. Safety and efficacy of different anesthetic regimens for parturients with COVID-19 undergoing Cesarean delivery: a case series of 17 patients. Canadian journal of anaesthesia = Journal canadien d'anesthesie.2020;67(6):655-663. 10.1007/s12630-020-01630-7

15. Chen R, Chen J, Meng QT. Chest computed tomography images of early coronavirus disease (COVID-19). Canadian journal of anaesthesia = Journal canadien d'anesthesie.2020;67(6):754-755. 10.1007/s12630-020-01625-4

16. Chen S, Liao E, Cao D, Gao Y, Sun G, Shao Y. Clinical analysis of pregnant women with 2019 novel coronavirus pneumonia. Journal of medical virology.2020. 10.1002/jmv.25789

17. Collin J, Byström E, Carnahan A, Ahrne M. Pregnant and postpartum women with SARS-CoV-2 infection in intensive care in Sweden. Acta obstetricia et gynecologica Scandinavica.2020. 10.1111/aogs.13901

18. Cooke WR, Billett A, Gleeson S, Jacques A, Place K, Siddall J*, et al.* SARS-CoV-2 infection in very preterm pregnancy: experiences from two cases. European journal of obstetrics, gynecology, and reproductive biology.2020. 10.1016/j.ejogrb.2020.05.025

19. Coronado Munoz A, Nawaratne U, McMann D, Ellsworth M, Meliones J, Boukas K. Late-Onset Neonatal Sepsis in a Patient with Covid-19. The New England journal of medicine.2020;382(19):e49. 10.1056/NEJMc2010614

20. De Socio GV, Malincarne L, Arena S, Troiani S, Benedetti S, Camilloni B*, et al.* Delivery in Asymptomatic Italian Woman with SARS-CoV-2 Infection. Mediterranean journal of hematology and infectious diseases.2020;12(1):e2020033. 10.4084/mjhid.2020.033

21. Dória M, Peixinho C, Laranjo M, Varejão AM, Silva PT. Covid-19 during pregnancy: a case series from an universally tested population from the north of Portugal. European journal of obstetrics, gynecology, and reproductive biology.2020. 10.1016/j.ejogrb.2020.05.029

22. Du Y, Wang L, Wu G, Lei X, Li W, Lv J. Anesthesia and protection in an emergency cesarean section for pregnant woman infected with a novel coronavirus: case report and literature review. Journal of anesthesia.2020. 10.1007/s00540-020-02796-6

23. Fan C, Lei D, Fang C, Li C, Wang M, Liu Y*, et al.* Perinatal Transmission of COVID-19 Associated SARS-CoV-2: Should We Worry? Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.2020. 10.1093/cid/ciaa226

24. Ferrazzi E, Frigerio L, Savasi V, Vergani P, Prefumo F, Barresi S*, et al.* Vaginal delivery in SARS-CoV-2 infected pregnant women in Northern Italy: a retrospective analysis. BJOG : an international journal of obstetrics and gynaecology.2020. 10.1111/1471-0528.16278

25. Gidlöf S, Savchenko J, Brune T, Josefsson H. COVID-19 in pregnancy with comorbidities: More liberal testing strategy is needed. Acta obstetricia et gynecologica Scandinavica.2020. 10.1111/aogs.13862

26. Govind A, Essien S, Karthikeyan A, Fakokunde A, Janga D, Yoong W*, et al.* Re: Novel Coronavirus COVID-19 in late pregnancy: Outcomes of first nine cases in an inner city London hospital. European journal of obstetrics, gynecology, and reproductive biology.2020. 10.1016/j.ejogrb.2020.05.004

27. Hantoushzadeh S, Shamshirsaz AA, Aleyasin A, Seferovic MD, Aski SK, Arian SE*, et al.* Maternal Death Due to COVID-19 Disease. American journal of obstetrics and gynecology.2020. 10.1016/j.ajog.2020.04.030

28. Hirshberg A, Kern-Goldberger AR, Levine LD, Pierce-Williams R, Short WR, Parry S*, et al.* Care of critically ill pregnant patients with COVID-19: a case series. American journal of obstetrics and gynecology.2020. 10.1016/j.ajog.2020.04.029

29. Hong L, Smith N, Keerthy M, Lee-Griffith M, Garcia R, Shaman M*, et al.* Severe COVID-19 infection in pregnancy requiring intubation without preterm delivery: A case report. Case reports in women's health.2020:e00217. 10.1016/j.crwh.2020.e00217

30. Inchingolo R, Smargiassi A, Moro F, Buonsenso D, Salvi S, Del Giacomo P*, et al.* The Diagnosis of Pneumonia in a Pregnant Woman with COVID-19 Using Maternal Lung Ultrasound. American journal of obstetrics and gynecology.2020. 10.1016/j.ajog.2020.04.020

31. Iqbal SN, Overcash R, Mokhtari N, Saeed H, Gold S, Auguste T*, et al.* An Uncomplicated Delivery in a Patient with Covid-19 in the United States. The New England journal of medicine.2020;382(16):e34. 10.1056/NEJMc2007605

32. Juusela A, Nazir M, Gimovsky M. Two cases of coronavirus 2019-related cardiomyopathy in pregnancy. American journal of obstetrics & gynecology MFM.2020:100113. 10.1016/j.ajogmf.2020.100113

33. Kalafat E, Yaprak E, Cinar G, Varli B, Ozisik S, Uzun C*, et al.* Lung ultrasound and computed tomographic findings in pregnant woman with COVID-19. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.2020. 10.1002/uog.22034

34. Kamali Aghdam M, Jafari N, Eftekhari K. Novel coronavirus in a 15-day-old neonate with clinical signs of sepsis, a case report. Infectious diseases (London, England).2020;52(6):427-429. 10.1080/23744235.2020.1747634

35. Karami P, Naghavi M, Feyzi A, Aghamohammadi M, Novin MS, Mobaien A*, et al.* Mortality of a pregnant patient diagnosed with COVID-19: A case report with clinical, radiological, and histopathological findings. Travel medicine and infectious disease.2020:101665. 10.1016/j.tmaid.2020.101665

36. Kelly JC, Dombrowksi M, O'Neil-Callahan M, Kernberg AS, Frolova AI, Stout MJ. False-Negative COVID-19 Testing: Considerations in Obstetrical Care. American journal of obstetrics & gynecology MFM.2020:100130. 10.1016/j.ajogmf.2020.100130

37. Khan S, Jun L, Nawsherwan, Siddique R, Li Y, Han G*, et al.* Association of COVID-19 with pregnancy outcomes in health-care workers and general women. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.2020. 10.1016/j.cmi.2020.03.034

38. Khan S, Peng L, Siddique R, Nabi G, Nawsherwan, Xue M*, et al.* Impact of COVID-19 infection on pregnancy outcomes and the risk of maternal-to-neonatal intrapartum transmission of COVID-19 during natural birth. Infection control and hospital epidemiology.2020;41(6):748-750. 10.1017/ice.2020.84

39. Khodamoradi Z, Boogar SS, Shirazi FKH, Kouhi P. COVID-19 and Acute Pulmonary Embolism in Postpartum Patient. Emerging infectious diseases.2020;26(8). 10.3201/eid2608.201383

40. Kuhrt K, McMicking J, Nanda S, Nelson-Piercy C, Shennan A. Placental abruption in a twin pregnancy at 32 weeks' gestation complicated by COVID-19, without vertical transmission to the babies. American journal of obstetrics & gynecology MFM.2020:100135. 10.1016/j.ajogmf.2020.100135

41. Lang GJ, Zhao H. Can SARS-CoV-2-infected women breastfeed after viral clearance? Journal of Zhejiang University Science B.2020;21(5):405-407. 10.1631/jzus.B2000095

42. Lee DH, Lee J, Kim E, Woo K, Park HY, An J. Emergency cesarean section on severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) confirmed patient. Korean journal of anesthesiology.2020. 10.4097/kja.20116

43. Li J, Wang Y, Zeng Y, Song T, Pan X, Jia M*, et al.* Critically ill pregnant patient with COVID-19 and neonatal death within two hours of birth. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.2020. 10.1002/ijgo.13189

44. Li N, Han L, Peng M, Lv Y, Ouyang Y, Liu K*, et al.* Maternal and neonatal outcomes of pregnant women with COVID-19 pneumonia: a case-control study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.2020. 10.1093/cid/ciaa352

45. Li Y, Zhao R, Zheng S, Chen X, Wang J, Sheng X*, et al.* Lack of Vertical Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, China. Emerging infectious diseases.2020;26(6):1335-1336. 10.3201/eid2606.200287

46. Liao J, He X, Gong Q, Yang L, Zhou C, Li J. Analysis of vaginal delivery outcomes among pregnant women in Wuhan, China during the COVID-19 pandemic. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.2020. 10.1002/ijgo.13188

47. Liu D, Li L, Wu X, Zheng D, Wang J, Yang L*, et al.* Pregnancy and Perinatal Outcomes of Women With Coronavirus Disease (COVID-19) Pneumonia: A Preliminary Analysis. AJR American journal of roentgenology.2020:1-6. 10.2214/ajr.20.23072

48. Liu W, Wang J, Li W, Zhou Z, Liu S, Rong Z. Clinical characteristics of 19 neonates born to mothers with COVID-19. Frontiers of medicine.2020;14(2):193-198. 10.1007/s11684-020-0772-y

49. Liu Y, Chen H, Tang K, Guo Y. Clinical manifestations and outcome of SARS-CoV-2 infection during pregnancy. The Journal of infection.2020. 10.1016/j.jinf.2020.02.028

50. Lokken EM, Walker CL, Delaney S, Kachikis A, Kretzer NM, Erickson A*, et al.* Clinical Characteristics of 46 Pregnant Women with a SARS-CoV-2 Infection in Washington State. American journal of obstetrics and gynecology.2020. 10.1016/j.ajog.2020.05.031

51. London V, McLaren R, Jr., Atallah F, Cepeda C, McCalla S, Fisher N*, et al.* The Relationship between Status at Presentation and Outcomes among Pregnant Women with COVID-19. American journal of perinatology.2020. 10.1055/s-0040-1712164

52. Lorenz N, Treptow A, Schmidt S, Hofmann R, Raumer-Engler M, Heubner G*, et al.* Neonatal Early-Onset Infection With SARS-CoV-2 in a Newborn Presenting With Encephalitic Symptoms. The Pediatric infectious disease journal.2020. 10.1097/inf.0000000000002735

53. Lowe B, Bopp B. COVID-19 vaginal delivery - a case report. The Australian & New Zealand journal of obstetrics & gynaecology.2020. 10.1111/ajo.13173

54. Lu D, Sang L, Du S, Li T, Chang Y, Yang XA. Asymptomatic COVID-19 infection in late pregnancy indicated no vertical transmission. Journal of medical virology.2020. 10.1002/jmv.25927

55. Lyra J, Valente R, Rosário M, Guimarães M. Cesarean Section in a Pregnant Woman with COVID-19: First Case in Portugal. Acta medica portuguesa.2020. 10.20344/amp.13883

56. Martinelli I, Ferrazzi E, Ciavarella A, Erra R, Iurlaro E, Ossola M*, et al.* Pulmonary embolism in a young pregnant woman with COVID-19. Thrombosis research.2020;191:36-37. 10.1016/j.thromres.2020.04.022

57. Mehta H, Ivanovic S, Cronin A, VanBrunt L, Mistry N, Miller R*, et al.* Novel coronavirus-related acute respiratory distress syndrome in a patient with twin pregnancy: A case report. Case reports in women's health.2020:e00220. 10.1016/j.crwh.2020.e00220

58. Penfield CA, Brubaker SG, Limaye MA, Lighter J, Ratner AJ, Thomas KM*, et al.* Detection of SARS-COV-2 in Placental and Fetal Membrane Samples. American journal of obstetrics & gynecology MFM.2020:100133. 10.1016/j.ajogmf.2020.100133

59. Peng Z, Wang J, Mo Y, Duan W, Xiang G, Yi M*, et al.* Unlikely SARS-CoV-2 vertical transmission from mother to child: A case report. Journal of infection and public health.2020;13(5):818-820. 10.1016/j.jiph.2020.04.004

60. Pereira A, Cruz-Melguizo S, Adrien M, Fuentes L, Marin E, Perez-Medina T. Clinical course of Coronavirus Disease-2019 (COVID-19) in pregnancy. Acta obstetricia et gynecologica Scandinavica.2020. 10.1111/aogs.13921

61. Perrone S, Deolmi M, Giordano M, D'Alvano T, Gambini L, Corradi M*, et al.* Report of a series of healthy term newborns from convalescent mothers with COVID-19. Acta bio-medica : Atenei Parmensis.2020;91(2):251-255. 10.23750/abm.v91i2.9743

62. Pierce-Williams RAM, Burd J, Felder L, Khoury R, Bernstein PS, Avila K*, et al.* Clinical course of severe and critical COVID-19 in hospitalized pregnancies: a US cohort study. American journal of obstetrics & gynecology MFM.2020:100134. 10.1016/j.ajogmf.2020.100134

63. Qadri F, Mariona F. Pregnancy affected by SARS-CoV-2 infection: a flash report from Michigan. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet.2020:1-3. 10.1080/14767058.2020.1765334

64. Qiancheng X, Jian S, Lingling P, Lei H, Xiaogan J, Weihua L*, et al.* Coronavirus disease 2019 in pregnancy. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.2020;95:376-383. 10.1016/j.ijid.2020.04.065

65. Salvatori G, De Rose DU, Concato C, Alario D, Olivini N, Dotta A*, et al.* Managing COVID-19-Positive Maternal-Infant Dyads: An Italian Experience. Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine.2020;15(5):347-348. 10.1089/bfm.2020.0095

66. Savasi VM, Parisi F, Patanè L, Ferrazzi E, Frigerio L, Pellegrino A*, et al.* Clinical Findings and Disease Severity in Hospitalized Pregnant Women With Coronavirus Disease 2019 (COVID-19). Obstetrics and gynecology.2020. 10.1097/aog.0000000000003979

67. Schnettler WT, Al Ahwel Y, Suhag A. Severe ARDS in COVID-19-infected pregnancy: obstetric and intensive care considerations. American journal of obstetrics & gynecology MFM.2020:100120. 10.1016/j.ajogmf.2020.100120

68. Shanes ED, Mithal LB, Otero S, Azad HA, Miller ES, Goldstein JA. Placental Pathology in COVID-19. American journal of clinical pathology.2020. 10.1093/ajcp/aqaa089

69. Sun M, Xu G, Yang Y, Tao Y, Pian-Smith M, Madhavan V*, et al.* Evidence of mother-to-newborn infection with COVID-19. British journal of anaesthesia.2020. 10.1016/j.bja.2020.04.066

70. Taghizadieh A, Mikaeili H, Ahmadi M, Valizadeh H. Acute kidney injury in pregnant women following SARS-CoV-2 infection: A case report from Iran. Respiratory medicine case reports.2020:101090. 10.1016/j.rmcr.2020.101090

71. Vallejo V, Ilagan JG. A Postpartum Death Due to Coronavirus Disease 2019 (COVID-19) in the United States. Obstetrics and gynecology.2020. 10.1097/aog.0000000000003950

72. Vlachodimitropoulou Koumoutsea E, Vivanti AJ, Shehata N, Benachi A, Le Gouez A, Desconclois C*, et al.* COVID19 and acute coagulopathy in pregnancy. Journal of thrombosis and haemostasis : JTH.2020. 10.1111/jth.14856

73. Wen R, Sun Y, Xing QS. A patient with SARS-CoV-2 infection during pregnancy in Qingdao, China. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.2020. 10.1016/j.jmii.2020.03.004

74. Wu C, Yang W, Wu X, Zhang T, Zhao Y, Ren W*, et al.* Clinical Manifestation and Laboratory Characteristics of SARS-CoV-2 Infection in Pregnant Women. Virologica Sinica.2020:1-6. 10.1007/s12250-020-00227-0

75. Wu X, Sun R, Chen J, Xie Y, Zhang S, Wang X. Radiological findings and clinical characteristics of pregnant women with COVID-19 pneumonia. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.2020. 10.1002/ijgo.13165

76. Wu Y, Liu C, Dong L, Zhang C, Chen Y, Liu J*, et al.* Coronavirus disease 2019 among pregnant Chinese women: Case series data on the safety of vaginal birth and breastfeeding. BJOG : an international journal of obstetrics and gynaecology.2020. 10.1111/1471-0528.16276

77. Xia H, Zhao S, Wu Z, Luo H, Zhou C, Chen X. Emergency Caesarean delivery in a patient with confirmed COVID-19 under spinal anaesthesia. British journal of anaesthesia.2020;124(5):e216-e218. 10.1016/j.bja.2020.02.016

78. Xiong X, Wei H, Zhang Z, Chang J, Ma X, Gao X*, et al.* Vaginal delivery report of a healthy neonate born to a convalescent mother with COVID--19. Journal of medical virology.2020. 10.1002/jmv.25857

79. Yan J, Guo J, Fan C, Juan J, Yu X, Li J*, et al.* Coronavirus disease 2019 (COVID-19) in pregnant women: A report based on 116 cases. American journal of obstetrics and gynecology.2020. 10.1016/j.ajog.2020.04.014

80. Yang H, Hu B, Zhan S, Yang LY, Xiong G. Effects of SARS-CoV-2 infection on pregnant women and their infants: A retrospective study in Wuhan, China. Archives of pathology & laboratory medicine.2020. 10.5858/arpa.2020-0232-SA

81. Yang P, Wang X, Liu P, Wei C, He B, Zheng J*, et al.* Clinical characteristics and risk assessment of newborns born to mothers with COVID-19. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.2020;127:104356. 10.1016/j.jcv.2020.104356

82. Yu N, Li W, Kang Q, Xiong Z, Wang S, Lin X*, et al.* Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study. The Lancet Infectious diseases.2020;20(5):559-564. 10.1016/s1473-3099(20)30176-6

83. Yu Y, Fan C, Bian J, Shen Y. Severe COVID-19 in a pregnant patient admitted to hospital in Wuhan. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.2020. 10.1002/ijgo.13232

84. Zeng Y, Lin L, Yan Q, Wei W, Yang BX, Huang R*, et al.* Update on clinical outcomes of women with COVID-19 during pregnancy. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.2020. 10.1002/ijgo.13236

85. Zhang ZJ, Yu XJ, Fu T, Liu Y, Jiang Y, Yang BX*, et al.* Novel Coronavirus Infection in Newborn Babies Under 28 Days in China. The European respiratory journal.2020. 10.1183/13993003.00697-2020

86. Zhu H, Wang L, Fang C, Peng S, Zhang L, Chang G*, et al.* Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia. Translational pediatrics.2020;9(1):51-60. 10.21037/tp.2020.02.06